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Abstract 
The rat strain TGR(mRen-2)27 is a monogenic model of hypertension 
expressing the mouse Ren-2 gene in a number of tissues. One of the main features of 
this model is that it exhibits elevated plasma prorenin levels which has been implicated 
in the phenotype of hypertension. To investigate the role elevated plasma prorenin 
plays in the hypertensive TGR(mRen-2)27 rat prorenin was expressed in a non-renal 
tissue distant from the renal juxtaglomerular apparatus which is the only known site of 
conversion of prorenin to active renin in rat. The transgene design consisted of the 
promoter elements of the human a 1 anti-trypsin gene, to direct expression of the 
transgene to the liver, fused to the mouse Ren2d  cDNA. 
This transgene was introduced into the rat genome by microinjection. Lines 
were established in both Sprague-Dawley outbred and Fischer/344 inbred rat strains 
and examined in detail. Expression analysis of the transgene in the lines TG2, TG3, 
TG7 and TG 12 showed detectable expression was limited to the liver, and that there 
was an elevation of plasma prorenin with no increase in plasma active renin. 
The percentage of plasma active renin that was transgene derived was greater 
than 80% and all lines studied showed pronounced left ventricular cardiac hypertrophy 
at an early age, which in the case of Fischer lines TG7 and TG12, was quantified by 
echocardiography. At six weeks of age lines TG7 and TG12 showed left ventricular 
mass indices (LVMI) of 3.5 as opposed to controls showing a LVMI of 1.6 at the 
same age. The results demonstrate that in the TGR((x 1 AT/Ren-2) rat extra-renal 
expression of Ren-2 prorenin, directly or indirectly, results in hypertension with 
extreme cardiac hypertrophy. This model also further refines our understanding of the 
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CHAPTER 1 
Introduction 
1.1 Classification of Hypertension 
As many as 50 million Americans have elevated blood pressure or are taking 
antihypertensive medication. This estimate is taken from the random sample of 
American adults in the National Health and Nutrition Examination Survey III. The 
prevalence of high blood pressure increases with age, is far greater for blacks than 
whites, and in both races is greater in less educated than more educated people. It is 
especially prevalent and devastating in lower socioeconomic groups. In young 
adulthood and early middle age, high blood pressure is more prevalent in men than for 
women, thereafter, the reverse is true (Rocella et al. 1989). Nonfatal and fatal 
cardiovascular diseases (CVDs) - including coronary heart disease (CHD) and stroke - 
and renal disease all increase in mortality risk progressively with higher levels of both 
systolic and diastolic blood pressures (Anderson et al. 1991). 
Individuals are classified as being hypertensive or normotensive by their blood 
pressure levels. These categories aid in prognosis, decisions of therapy, and 
concentrate efforts on individuals who are most likely to benefit from treatment. The 
US Joint National Committee for Detection, Evaluation and Treatment of High Blood 
Pressure (JNC V), (JNC V 1993) defined the optimal blood pressure as a systolic 
blood pressure less than 120 mm Hg and a diastolic blood pressure less than 80 mm 
Hg. The high normal range of blood pressure in an individual is a systolic blood 
pressure (SBP) reading between 130 and 139 mm Hg or a diastolic blood pressure 
(DBP) reading between 85 and 89 mmHg. High systolic (~! 140mm Hg) or diastolic 
(~! 90 mm Hg) pressure, when confirmed on two or more visits, is diagnosed as 
hypertension. Hypertension is further categorised into four stages corresponding to the 
patient's level of systolic and diastolic blood pressure. The most common form of 
hypertension is stage 1 (80%) with stage four the least common (3%) (See table 1.1). 
Despite the practicalities of this system it is necessary to be aware that the cut-off 
points on this scale represent an operational guideline and not a biological distinction 
between hypertension and normotension. Population characteristics such as age, 
gender and race all influence the prevalence of hypertension (Hollenberg 1992). 
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Age has the greatest impact, using the JNC V criteria, with 65% of those aged 
~!80 years displaying varying degrees of hypertension. Gender plays a less significant 
role than other demographic factors in the epidemiology of hypertension. An example 
of one of the outcomes of hypertension in the different sexes is that coronary artery 
disease occurs less frequently in women than men until 6-10 years post-menopause. 
After the menopause, considerations for anti-hypertensive therapy selection in women 
become identical to those in men. In the case of race, recent studies support the view 
that blacks have higher blood pressure than whites at all ages (Manatunga et al. 1993). 
There is evidence for structural changes in the resistance vessels of the peripheral 
vasculature and the kidney, which are apparent in young blacks, both may possibly be 
related to the development of hypertension. 
Table 1.1 
Classification of Blood Pressure for Adults Aged 18 Years and Older* 
Category 	Systolic, mmHg Diastolic, mmHg 
Normal 	 <130 	 <85 
High Normalt 	 130-139 85-89 
Hypertensiontt 
Stage 1 140-159 90-99 
Stage 2 160-179 100-119 
Stage 3 180-209 110-119 
Stage 4 ~!210 ~!120 
*Adapted from JNC V (JNC V 1993) 
tOptimal blood pressure with respect to cardiovascular risk is less than 120 mmHg 
systolic and less than 80 mmHg diastolic. However, unusually low readings are 
evaluated for clinical significance. 
ttBased on the average of two or more readings taken at each of two or more visits 
after an initial screening. 
1.1.1 Essential Hypertension: 
No single factor has been found to be responsible for the onset of essential or 
idiopathic hypertension (Ayman 1934; Kurtz et al. 1993). Early stage essential 
hypertension may be due to a small increase in cardiac output, possibly caused by 
sympathetic overactivity. Later in the disease the cardiac output is normal but 
peripheral resistance is increased. In essential hypertension the baroreceptor reflexes 
operate at a higher pressure. Increased blood pressure should stimulate a bradycardia 
through the baroreceptor mechanism of the carotid sinus, but this does not occur in 
essential hypertension. 
There is a strong genetic tendency to develop essential hypertension, which can 
be exacerbated by factors such as obesity, stress, and excessive salt intake. It has been 
postulated that a defect in renal salt management may underlie many cases of essential 
hypertension. Minor disturbances in renal function, below the level of detection could 
lead to a gradual accumulation of salt and water in the body, resulting in progressive 
increase in arterial pressure. 
In benign essential hypertension arteriosclerosis of the major renal arteries, and 
changes in the intrarenal vasculature, occurs (Brown et al. 1974). The small vessels 
and arterioles exhibit myointimal thickening and the vessel wall becomes hyalinized. 
Concentric reduplication of the internal elastic lamina and endothelial proliferation 
produce an "onion skin" appearance (Hsu et al. 1980). 
In only 10% of hypertension cases is the cause of the hypertension known, these 
are termed secondary hypertension. These causes can be divided into renal, endocrine, 
cardiovascular, pregnancy and drug related. 
1. Renal causes. Renal diseases are the most common causes of secondary 
hypertension (80% of cases) (Conn et al. 1972), see table 1.2. 
Arthermatous renal artery stenosis (ARAS): 
Patients usually present with atheroma elsewhere before developing atheroma of 
the renal arteries and also should be considered in patients with histories of myocardial 
ischaemia or stroke. Stenosis usually affects the proximal portion of the renal arteries 
and in nearly 30% of the cases is predominantly ostial (Sos et al. 1983). In ARAS 
stenosis progression is common. Quality of blood pressure control does not seem to 
influence progression and between 8%-17% of stenoses progress to occlusion in 3-4 
years (Schreiber et al. 1984) 
Table 1.2 
	 ru 
Renovascular 	I 	Renal Parenchymal 
Atherosclerosis 
Fibromuscular dysplasia (FMD) 
Takayasu's arteritis 
Middle aortic syndrome 
Neurofibromatosis 
Dissecting aneurysm aorta 
Renal artery aneurysm 
Renal arteriovenous fistula 
Radiation arteritis 









Obstructive uropathies and hydronephritis 
Renin.-secreting tumours (eg. Wilms tumour) 
Renal Trauma 
(Adapted from the Essential Hypertension ed Laragh and Blumefield) 
2. Endocrine causes. 
Conn's Syndrome: True Conn's syndrome, as the classic form of 
mineralocorticoid excess with hypertension, is due to an aldosterone-secreting adenoma 
of the adrenal cortex. The disease is more often found in women than in men. Several 
patients have been described with both acromegaly and Conn's syndrome. The 
hypertension is accompanied by hypokalaemia, contraction of body potassium content 
and expansion of body sodium content. 
Acromegaly: Acromegaly is the result of excessive production of growth 
hormone in an adult subject. The usual cause of acromegaly is a tumour of the anterior 
pituitary gland producing an excess of growth hormone. Due to varied definitions of 
'hypertension' and of methods of blood pressure measurement, accurate estimates of 
the prevalence of hypertension in acromegaly are difficult. Despite this, many series 
report high blood pressure in between 18-45% of cases, with the greatest frequency 
seen in older patients and women (Fraser et al. 1989). 
Cushing's Syndrome: Cushing's syndrome results from a prolonged excess of 
glucocortoids, notably cortisol. Hypertension, occurring in about 75-85% of patients 
is a frequent accompaniment of this uncommon disease (Padfield et al. 1993). 
Cushing's syndrome is caused by an abnormality of the anterior pituitary gland. Such 
primary pituitary disease or dysfunction of the hypothalamic-pituitary axis accounts for 
70% of all cases. 
Phaeochromocytoma: Phaeochromocytomas are tumours of the chromaffin cells. 
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Despite the majority of these tumours lying within the adrenal medulla, they can also be 
widely distributed at other sites where chromaffin cells occur, such as in apposition to 
sympathetic nerve plexuses in the neck, chest, urinary bladder, rectum, testes or 
ovaries. These tumours can secrete excessive quantities of noradrenalin and adrenalin, 
together with the catecholamine precursors dopamine and DOPA. Noradrenalin is the 
hormone predominantly released, and seems to be ubiquitous in non-familial 
phaeochromocytomas. Noradrenalin causes peripheral vasoconstriction, elevation of 
both systolic and diastolic pressures and reflex bradycardia; adrenalin raises systolic 
pressure, lowers the diastolic pressure and increases heart rate. 
Cardiovascular causes. 
Coarctation of the aorta: Coarctation of the aorta results from an abnormality in 
development of the aortic arch system, such that there persists a structural narrowing of 
the aorta usually in its descending intrathoracic course. An extensive collateral arterial 
system develops to circumvent the coarctation and thus supply adequate blood to the 
lower part of the body. Hypertension, readily detected in the upper limbs, is indicative 
of coarctation (Rocchini et al. 1976). 
Pregnancy. 
Hypertension in the early stages of pregnancy is usually essential hypertension. 
However, the definition of hypertension during pregnancy is arbitrarily taken as 
systolic BP in excess of 140 mmHg and/or a fourth phase diastolic over 90 mmHg 
(JNC V 1993)(table 1.1). Pre-eclampsia or toxaemia of pregnancy is diagnosed when 
hypertension develops in the last three months and is associated with oedema and 
proteinuria. 
Drugs. 
Oestrogen-containing contraceptives, other steroids, liquorice and vasopressin 
may all cause hypertension. Oestrogens cause a rise in the level of plasma 
angiotensinogen concentration. Due to the absence of a compensatory fall in plasma 
concentration of renin, plasma levels of angiotensin II rise, contributing to blood 
pressure elevation (JNC V 1993). 
1.1.2 Malignant Hypertension: 
Malignant hypertension is a rare disorder with a high but declining mortality and 
morbidity from renal cerebral and cardiac complications. It is a disorder that presents 
with a rapidly and deteriorating renal function. Of the patients with essential 
hypertension only 1-2% are thought to develop malignant phase hypertension, 
precipitated by a sudden rise in blood pressure (Houston 1989). Clinical features of 	
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malignant hypertension include visual blurring, dizziness, headaches, fatigue and 
weight loss. However, many patients remain asymptomatic (Kincaid-Smith 1982) 
The early reports of malignant hypertension described the condition without 
treatments (Keith et al. 1928). Macroscopic changes were not seen in the kidney with 
the main renal findings being at the microscopic level, with diffuse changes affecting 
smaller arteries and arterioles, but not larger arteries. Specifically, intimal hyperplasia 
with deposits of lipid, fatty acids and calcium resulted in significant luminal narrowing 
(Keith et al. 1928). A further series of cases described a degree of glomerular capillary 
tuft collapse, capillary thrombosis, glomeruloscierosis and evidence of crescent 
formation in addition to the arteriolar changes previously reported. Onion skinning' 
intimal proliferation, with concentric lamellae of basement membrane and 
granulofilamentous material and a thin layer of hypertrophic medial cells stretched 
around the circumference, was shown by light microscope studies of affected kidneys 
to be caused by smooth muscle cells (Hsu et al. 1980; Dunn 1982). Electron 
microscopy showed that fibrinoid necrosis consisted of three components, fibrin, 
fibrinoid and cellular necrosis. Arterial luminal thromboses consisted of both fibrin 
and platelets (Dunn 1982). As a result of natriuresis and diuresis the renal renin-
angiotensin system is activated. This may cause a cycle of increasing blood pressure 
and continuous renal damage. 
1. 1.3 Treatment of Essential and Malignant Hypertension: 
General Measures: 
Weight reduction is one of the most common 'life style' alterations made in 
clinically hypertensive patients (Birkenhager et al. 1984; Ward 1990; Hollenberg 
1992). This leads to a fall in blood pressure and a reduction of the artefactually 
increased cuff measurements. Weight reduction in patients 10%, or greater, above 
their ideal weight enhances the blood-pressure lowering effects of concurrent 
antihypertensive agents. Reducing the intake in a heavy drinker leads to a small 
reduction in blood pressure. Salt restriction requires reduction of dietary salt. This 
often takes the form of no added salt at the table. Regular exercise in conjunction with 




Angiotensin-converting enzyme (ACE) inhibitors, such as Captopril and 
Enalapril, block the conversion of angiotensin Ito angiotensin II, promote vasodilation 
and decrease aldosterone levels. Angiotensin II is a potent vasoconstrictor. ACE 
inhibitors also block the degradation of bradykinin, a vasodilator, which results in 
increased levels of plasma bradykinin. Calcium antagonists such as Nifedipine or 
Verapamil block inward movement of calcium ions across cell membranes and cause 
smooth-muscle relaxation reducing blood pressure primarily by arteriolar dilatation, but 
also by negative inotropy (force of cardiac contraction) (Opie 1990). Alpha-i 
adrenergic antagonists such as Prazosin and Indoramin are post-synaptic alpha-
blockers causing vasodilation and are very effective hypotensive drugs. 
Diuretics: 
Loop diuretics (e.g., Frusemide) and thiazide diuretics (e.g., Cyclopenthiazide) 
are equally effective at lowering blood pressure and work by decreasing plasma volume 
and extracellular fluid volume followed by decreasing total peripheral resistance and 
normalisation of cardiac output. Thiazides are often preferred as the duration of action 
is longer and the diuresis is less severe. Loop diuretics are restricted to those with 
cardiac or renal impairment for whom an additional diuretic effect is required. 
Beta-adrenergic antagonists: 
Beta-adrenergic antagonists decrease cardiac output and increase total peripheral 
resistance. According to the JNC V report, beta-adrenergic antagonists should be used 
as the optimal first steps of pharmacological intervention in hypertension. This view is 
disputed by Weber who draws attention to the limitations of the study (SHEP) from 
which these conclusions were made and suggests ACE inhibitors may be as effective 
(Weber et al. 1990). 
1.2 Genetics of Hypertension 
Genetic analysis of essential hypertension is hampered by the fact that the disease 
is polygenic and heterogeneous in nature (Ward 1990). Essential hypertension is likely 
to involve epistatic and ecogenetic interactions (Lindpaintner 1993). Population studies 
(Miall et al. 1963) have shown that between 12-35% of blood pressure variation can be 
attributed to genetic causes. Studying the genetics of hypertension has taken the form 
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of sib-pair analysis, kindreds with a high incidence of the disease, and animal models 
of genetic hypertension. The results are applied to humans to identify genes that have 
an influence on the clinical features of this polygenic disease. 
The study performed by Zinner et al (Zinner et al. 1971), on children aged 2-14 
years from 192 families, did demonstrate familial aggregation. By studying the 
distribution of mean family scores it was shown that they differed significantly from 
the expected normal distribution. A weak correlation between infant blood pressure 
and maternal blood pressure was found at birth, but a significant relationship with 
paternal blood pressure was not found until one month old (Zinner et al. 1985). At 
birth, infant blood pressure could be affected by the intra-uterine environment which in 
turn may be influenced by both maternal genes and environment. 
Biochemical and physiological abnormalities have been shown in hypertensive 
families and animals, but results are difficult to interpret whether a particular 
abnormality is a cause or consequence of the disease. Despite no single biochemical 
defect being shown to be causative for essential hypertension, these studies provide 
indications as to the genes responsible for blood pressure regulation (Padfield et al. 
1993). 
Restriction fragment length polymorphism (RFLP) analysis takes advantage of 
variation in restriction sites present in the human genome to map polymorphisms that 
segregate with the desired trait (see figure 1.1). Polymerase chain reaction (PCR) is 
now use in a similar fashion to amplify regions of the genome which varies from 
individual to individual. These approaches have proved successful for diseases having 
Mendelian inheritance (Cawthon et al. 1990). For polygenic traits it may not be 
possible to study a homogeneous population as different families segregate from 
different loci. A quantitative trait that is a continuous variable, e.g. blood pressure, is 
often best analysed as a quantative phenotype, which avoids making strong 
assumptions about the form of its association with the disease of interest. 
Liddles Syndrome (pseudoaldosteronism) has long been recognised as having an 
autosomal dominant mode of inheritance with constitutive activation of the Na+H+ 
exchange channel in the distal tubule (Botero-Velez et al. 1994). Recently 
polymorphisms for the gene coding for the b subunit of the epithelial sodium channel 
have been found to be linked with hypertension in five kindreds with the syndrome 
(Shimkets et al. 1994). It is therefore quite possible that other single gene defects may 
be identified causing hypertension in certain kindred (Kurtz 1994). 
Glucocorticoid remediable hyperaldosteronism (GRA) does not reliably exhibit 
clinical features or blood chemistry that would have allowed clear distinction from 
essential hypertension after standard investigations. The diagnosis of GRA requires 
demonstrating elevated urinary excretion of steroid metabolites 1 8-hydroxycortisol and 
18-oxocortisol. Lifton et al identified linkage of GRA with an RFLP occurring at a 
fusion event between the ACTH responsive regulatory sequences of the 1 113-
hydroxylase gene and the coding sequences of the aldosterone synthase gene. This 
resulted in ectopic expression of aldosterone synthase in the adrenal zona fasciculata in 
response to stimulation by ACTH rather than angiotensin II (Ang II) or potassium 
(Lifton et al. 1992). 
One of the most intensely studied blood pressure regulatory systems is the renin-
angiotensin-system. There is a Bgl II RFLP in the rat renin gene as a result of a 
variable number of tandem repeats (VNTR) of a 38bp sequence present in the first 
intron. Several renin alleles have been identified in hypertensive and normotensive 
strains of rat. 
Using established rat strains Kurtz et a! (1990) identified one or two SHR renin 
alleles in a SHR/Lewis cross resulting in higher blood pressure in the animals which 
inherited the SHR allele (Kurtz et al. 1990). Both SHR and inbred Dahl salt-
hypertension resistant rats (SR/Jr) were found to carry the same renin allele based on 
studies of the first intron VNTR and a Hind III site in the fifth intron which 
distinguishes the allele. This meant that in an F2 cross of the inbred salt-hypertension 
sensitive Dahl rat (SS/Jr) and SHR, the SHR contributed the r allele which lowered 
blood pressure. Therefore in the F2 progeny homozygous for the s allele derived from 
S S/Jr showed higher blood pressure was seen and rats homozygous for the r allele 
derived from SHR showed lower blood pressure (Rapp et al. 1994). 
Two groups have shown linkage of loci with basal blood pressure variance in 
response to sodium loading in TG2 SHRSP/WKY crosses. Jacob et al (1991) 
developed a series of microsatellite markers for the rat based on simple sequence 
repeats (SSR) (Jacob et al. 1991). Hubert et al (1991) used a combination of 
minisatellite probes, microsatellite markers and an RFLP previously identified in the 
SHRSP renin gene (Hubert et al. 1991). In common to both studies, a locus on 
chromosome 10 named Bpl or BP/SP-1 respectively, showed significant linkage 
disequilibrium with sodium loaded blood pressure. The locus was identified by both 
groups to be in the region of the angiotensin converting enzyme gene. The sequences 
for the respective ACE cDNAs, as obtained by screening cDNA libraries from SHRSP 
and WKY, showed that they differed by 5 nucleotides in the coding regions, only one 
of which resulted in an amino acid substitution (Lys207->Arg207) in SHR-SP. 
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Figure 1.1 
The detection and inheritance of a restriction fragment length polymorphism (RFLP). A 
probe P detects two DNA polymorphisms when the DNA is cut by a certain restriction 
enzyme (RE). The pedigree of the dominant disease phenotype D shows linkage of the D 
locus to the RFLP locus: only child 8 is a recombinant. 
Enzymatic analysis revealed similar Km and Vmax for ACE extracted from lung 
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tissue from both strains (Koike et al. 1994). However, another study failed to identify 
linkage between ACE alleles and hypertension in an F2 (SHR x WKY) population 
using CA repeat elements to differentiate ACE alleles, but found linkage in an F2 (Dahl 
SS/Jr x MINS) population (Deng et al. 1992). 
Phenylethanolamine N-methyl transferase (PNMT), an enzyme involved in 
catecholamine synthesis, has been found to be elevated in the brains of SHR-SP. The 
gene for the enzyme has been mapped to the region 17q22-17q24 in humans which is 
within the conserved linkage group syntetic to the region in the rat where the locus 
BP/SP-1 (or Bp I) was found (Bell 1992). The PNMT gene has now been located to 
Chromosome 10 in the rat, but no sequence differences were identified between the 
cloned genes obtained from SHRSP and WKY genomic DNA libraries, including 1.0 
kb of 5' sequence containing known regulatory regions and all exons (Koike et al. 
1994). 
In addition to the RAS, other regulatory systems potentially involved in blood 
pressure homeostasis have been implicated. The kallikrein gene family or closely 
linked genes has been marked with an RFLP using a pancreatic kallikrein cDNA probe 
which cross hybridised with a number of closely related kallikrein genes. This 
demonstrated that inheritance of the SHR allele in recombinant inbred strains derived 
from SHR and BN progenitors, is associated with significantly greater median systolic, 
diastolic and mean blood pressures (Pravenec et al. 1991). 
The results of linkage between candidate genes and hypertension in animal 
models of genetic hypertension can not be directly translated into the human situation. 
Association studies in humans look for a difference in the observed frequency of an 
allele at a marker locus comparing affected cases to unaffected, unrelated controls and 
for evidence of the loss of expected random segregation of alleles in a population. An 
allele is said to exhibit linkage disequilibrium with a trait if it occurs at a significantly 
higher frequency in the affected group compared with the unaffected control group 
(Griffiths et al. 1993). Despite linkage of an allele, however, causality is not implied. 
One allele may lie close to another which is responsible for the trait and be in linkage 
disequilibrium with it. 
Linkage studies test for a departure in the random segregation of both traits and 
genetic markers in families and look for evidence of excess sharing of a particular allele 
in affected relatives that is not consistent with random Mendelian segregation (Lander et 
al. 1994). Sibling or relative pairs may be examined, but analysis can be complicated 
by incomplete or delayed penetrance of the phenotype. Both these methods are very 
dependent on a low likelihood of recombination events (<1%) occurring between the 
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marker and the trait. 
In the case of polygenic disease, the relatively small contribution to the overall 
phenotype made by a single locus may make its effects too small to detect by allele 
sharing methods (Soubrier 1993). A different approach is to search directly for 
mutations in candidate genes. Sequence variations do not always alter function as they 
may not alter the amino acid sequence or they may occur in non-coding regions, but a 
mutation can be followed through a pedigree and its relationship with a phenotype be 
ascertained (Lifton et al. 1992; Lifton et al. 1993). 
A sib-pair linkage study using a dinucleotide repeat sequence 3' of the 
angiotensinogen gene, looked at hypertensive siblings from Salt Lake City and Paris. 
The study found a significant excess of shared alleles in male Parisian hypertensive 
siblings, but greater statistical significance was achieved when severe hypertensives 
from both populations were analysed together (Jeunemaitre et al. 1992). Fifteen 
angiotensinogen variants were identified and sequenced, five with 5' nucleotide 
substitutions and ten with silent or missense variants. Only variants with the resulting 
amino acid substitutions M235T and T 1 74M showed linkage disequilibrium, both 
elevated blood pressure and increased plasma angiotensinogen levels were found in 
heterozygote and homozygote M235T carriers (Jeunemaitre et al. 1992). Substrate 
level may well be important as the Km for the enzymatic cleavage of angiotensinogen 
by renin is close to the plasma level. Two groups have reported linkage of the 
angiotensinogen locus with pre-eclampsia, using the 3' dinucleotide repeat sequence in 
a linkage study and the M235T variant in an association study (Arngrimsson et al. 
1993; Ward et al. 1993). 
Two studies have shown linkage of hypertension, but not obesity, with the 
insulin receptor (RI-) allele based on an Rsa 1 RFLP occurring from the insertion of a 
CA repeat sequence in intron 9 (Ying et al. 1991). This result is of interest due to the 
association of insulin resistance with essential hypertension. Conflicting results were 
obtained using a microsatellite polymorphism located in intron 2, where derived allele 
frequencies showed similar distributions between hypertensive and normotensive 
subjects suggesting that the causative polymorphism may lie closer to intron 9 than to 
intron 2 (Zee et al. 1993). An association study has recently described a marker in 
close proximity to the cx-adducin locus and hypertension (Casari et al. 1995). This 
membrane skeleton protein was previously implicated as a potential factor in the genetic 
hypertension of the MHS rat by altering ion transport (Bianchi et al. 1984). 
These results support the view that variants of 'candidate' genes may contribute 
to the heritable factors of an individual's variation in blood pressure and affect their 
subsequent response to the environment (Harrap 1994). The important contribution to 	
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blood pressure homeostasis of the RAS and the finding of genetic polymorphisms 
occurring in components of this system in both rat models and in humans, has led 
directly to the study of the contribution of individual genes, in particular by alterations 
in the regulation of their expression and function. New methods, in particular 
transgenesis, have been developed which may help identify how hypertension might 
result from altered gene regulation and function (Ganten et al. 1991). 
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Figure 1.2 The renin-angiotensin system, biochemical pathway and physiological consequences. 
1.3 Prorenin 
In 1971 Lumbers (Lumbers 1971) discovered that an inactive form of human 
renin could be activated by partial hydrolysis which led to the postulated existence of 
prorenin, a renin precursor. It was only in 1981 that direct evidence was reported for 
the fact the synthesis of renin involved a "pro" form (Morris et al. 1981). Any 
physiological role for prorenin remains to be shown except from its part in the 
production of active renin. Production of the deca-peptide angiotensin I (Al) by the 
action of renin on liver derived angiotensinogen is the rate limiting step of the renin- 
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angiotensinogen system (RAS). The biologically active peptide produced by this 
cascade is angiotensin II, an octapeptide that is known to play a pivotal role in blood 
pressure regulation and sodium-potassium homeostasis (Peach 1977; Vecsei et al. 
1978). 
The primary translation product of the renin mRNA is preprorenin (Morris et al. 
1983). The 2kDa signal sequence directs preprorenin to the lumen of the rough 
endoplasmic reticulum for processing to prorenin. In the case of the mouse Ren2 renin 
gene the preprorenin is 45kDa which is then converted to a 43kDa prorenin. In 
contrast to other renin genes the product of the mouse Ren-2 gene generates a prorenin 
that is not glycosylated (Paul et al. 1988). 
It is thought that these sugar moieties may have some effect on conversion of 
prorenin to renin but are not essential. Baxter et al (Baxter et al. 1989) transfected 
AtT-20 cells with a human preprorenin expression vector in which the glycosylation 
sites had been mutated and found that the cells actually processed more prorenin to 
renin than normally glycosylated preprorenin. This suggests that these sugar moieties 
may regulate or retard processing of prorenin to renin. 
Aspartyl proteases have similar three-dimensional structures and the structures of 
pepsinogen, Rhizopus pepsin, and penicillopepsin have been reported as has that of 
recombinant human renin (Sielecki et al. 1989). The structural cores and active sites of 
renin are highly conserved with other aspartyl proteases. Despite the similarities there 
are variations in the surface residues that are critical for the differences in substrate 
specificity. These include the 'flap" areas; the carboxy terminal domains that may 
affect the pH profile, allowing renin to have activity at a relatively high pH of 5.5-7.5; 
and the carbohydrate moieties at the glycosylation sites, which may affect intracellular 
transit time (Paul et al. 1988). Protein modelling has shown that the pro-segment of 
prorenin can fit into the substrate binding cleft of the renin molecule and that more than 
three ionic interactions between the pro-segment and renin contribute to keeping the 
prorenin structure in an inactive form (Shiratori et al. 1990). 
Secreted prorenin is the product of the constitutive pathway (Pratt et al. 1987). 
The regulation of this pathway is minimal with pro hormone being delivered to the cell 
surface at a constant rate (Kelly 1986). The primary product of the regulated secretory 
pathway is active renin (Pratt et al. 1987). This pathway accumulates secreted 
proteins, releasing them in response to physiological stimuli. This response is 
mediated through the dense secretory granules of the juxtaglomerular cells which also 
serve as the major site of prorenin conversion to renin (Taugner et al. 1986). Certain 
strains of mouse which carry a gene duplication for renin have expression in the 
submaxilliary gland and this also contributes significantly to the level of circulating 	
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renin (Mullins et al. 1989). 
Activation of prorenin occurs by proteolytic cleavage of the 43 amino acid pro-
segment after the dibasic Lys Arg residues in all species (Catanzaro et al. 1983). The 
first amino acid of renin is a leucine. The "maturase" has not yet been conclusively 
defined although any candidate enzyme would have to be able to activate prorenin, 
correctly cleave the pro-segment, lack any renin degradation activity and colocalise 
within the renin secretory granules. In the human kidney cathepsin B has been 
proposed as the renin maturase (Wang et al. 1991). Cathepsin B activates crude 
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Figure 1.3 Schematic representation of the structure of human prorenin, deduced from 
the known structure of pepsinogen and human renin (Sielecki et al. 1989; Shiratori et al. 
1990) and the peptide sequences involved in processing of preprorenin to active renin 
(Hsueh et al. 1991). 
preparations of human prorenin and decreases its molecular weight (Takahashi et al. 
1992). It has also been shown to correctly cleave the pro-segment, does not degrade 
renin, and colocalises with the secretory granules (Taugner et al. 1986). 
Prorenin can be reversibly activated by acidification or cryoactivation (Leckie et 	
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al. 1980). These result in a conformational change where the pro-segment is removed 
from its normal inhibitory position. It is possible that there is local activation of this 
sort in a given organ where the local prorenin level could be much higher than in the 
circulation. 
Prorenin is an unusual zymogen as it is present at a much higher concentration 
than renin in the circulation of humans. Possibly as much as 90% of total renin (the 
sum of active and inactive renin) in humans is prorenin (Sealey et al. 1980). It is 
possible that prorenin is present in plasma at such high concentrations to act as a pool 
of potential renin, supplementing renin release from the kidneys. 
However, if plasma prorenin is not a pool of potential renin then there are two 
obvious possibilities: 1) prorenin is a functionless protein or, 2) it has a function of its 
own that does not require cleavage of the pro-segment. Osmond, Sealey & Mackenzie 
(1991) (Osmond et al. 1991) put forward six possible functions of prorenin. 
Prorenin could be a source of "quick renin" so that it would be rapidly 
converted to renin in the circulation, only if there is some way of activating it 
endogenously. 
Prorenin could play a role in circulation that is not mediated by renin but 
within the bounds of the known physiological effects of the renin angiotensin system. 
Prorenin could have a direct effect, unrelated to the reported actions of renin 
angiotensin. 
Prorenin may be a vehicle for transporting renin in an inactive form to a given 
target organ where it is either activated to renin or acts directly with a related function to 
the known effects of renin angiotensin. 
Prorenin may be a vehicle for transporting renin in an inactive form to a given 
target organ where its effect is outwith the known effects of renin angiotensin. 
Prorenin in the circulation may merely be overflow from renal and (or) 
extrarenal sources. 
The clinical implications of plasma prorenin levels are apparent in a number of 
conditions. For the most part, in normal individuals prorenin increases with chronic 
volume depletion, during the luteal phases of the menstrual cycle and pregnancy 	
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(Sealey et al. 1986; Troffa et al. 1991). 
Patients with diabetes mellitus (Types I & II) often exhibit elevated plasma 
prorenin levels, and these have been implicated as a potential marker of nephropathy. 
It also has been found that elevated prorenin levels are an indicator of vascular 
complications in Type I diabetes mellitus (Luetscher et al. 1989). 
The rise in circulating prorenin seen in diabetes has been hypothesised to be the 
result of impaired conversion of prorenin to renin in the kidney (deLeiva et al. 1976). 
This would suggest that either a diabetic kidney has defective storage granules or 
impaired proteolytic processing. In support of this is the report that in the 
streptozotocin diabetic rat there is defective prokallikrein-to-kallikrein conversion and 
decreased levels of cathepsin B. 
1.4 Renin 
Renin is a single chain glycosylated carboxypeptidase of MW 4lkD. It cleaves 
angiotensinogen, with a degree of specificity which is unlike other members of the 
aspartyl protease family, with an optimal function at pH 5.5 - 6.0 (Baxter et al. 1991; 
Campbell et al. 1991). The active site of renin lies in the cleft between the two lobes of 
the protein. 
B2 Ren-2d, Ren-2h 	1 kb 
M3 All mouse renin genes 	 M4 Ren-id 
LJM2 Ren-2d 	 lAP Ren-2d 
B 1 Mouse, rat and human renin genes 
Figure 1.4 
Basic structure of murine genes. The nine exons (solid boxes) and eight introns (solid line between 
exons) are shown. TAP, intracisternal A particle (Sigmund et al. 1991). 
Both human and rat genomes contain a single copy of the renin gene on 	
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chromosome 1 and chromosome 13 respectively (Sigmund et al. 1991). In the mouse 
the renin structural genes also reside on chromosome 1 and are tightly linked to the Rnr 
locus. These are expressed highly in the kidney, but in mice high expression is also 
found in the submaxillary gland (SMG). Strains of mouse such as C5713L16 and 
Balb/c have one renin gene (Ren-]c), but certain strains such as DBA and Swiss have 
two (Ren-ld and Ren-2d) (Field et al. 1984). Ren-2d is thought to have arisen as a 
result of a gene duplication event 2.5 - 5.5 million years ago (Dickinson et al. 1984; 
Holm et all. 1984) and it encodes a thermolabile, non-glycosylated isozyme, present at 
high levels in the granular convoluted tubules of the SMG. In two renin gene mice 
Ren-ld is expressed mainly in the JGA cells of the kidney at an approximately 
equivalent level to Ren-2d expression in the SMG on a per cell basis. Field and Gross 
(1985) demonstrated that all three mouse genes were expressed approximately 
equivalently in the kidney (Field et al. 1985). 
Table 1.3 
Tissue Cell Type Genes 
Kidney Juxtaglomerular Ren 1 c=Ren- 1 d=Ren-2d 
Submandibular Gland Glomerular Convoluted 
Tubules  
Ren-2d>>Ren 1 c>>Ren- 1 d 
Foetal Adrenal Developing Cortex Ren-2d=Ren-ld=Renlc 
Adult Adrenal X-zone, Zona Fasiculata Ren-2d=Ren- 1 d>>Ren 1 c 
Testes Interstitial Leydig Cells Ren-ld>Ren-2dRen1c 
Ovary Theca, Corpus Luteum Ren-2d=Ren- 1 d,Ren 1 c 
Anterior Prostate Glandular Epithelium Ren 1 c>>Ren- 1 d=Ren-2d 
Foetal Subcutaneous Specific population of 
Fibroblasts 	 I  
Ren 1 c=Ren- 1 d>Ren-2d 
Adapted from (Sigmund etal. 199 1) 
All mouse renin genes consist of 9 exons and 8 introns with a high degree of 
homology between cDNA sequences, 97% between Ren-]c and Ren-2d and 99% 
between Ren-lc and Ren-ld ( Sigmund et al. 1991). Both types of mouse strain are 
inducible with androgen showing higher levels of expression particularly in male 
mouse SMG, but also in female rat and mouse liver. 
Two highly repetitive elements have been mapped within the renin locus: a B2 
repetitive element is unique to the 5 region of the Ren-2d gene and a B 1 element is 
present within the 5' flanking region of all three mouse genes. An 0.5kb insertion 
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flanked by five nucleotide direct repeats, designated M3 (Mouse  insertion 3), reside 
within 80bp of the transcription start site of all three mouse genes. A partial 
intracistemal A particle (lAP) genome lies 1kb 3' of exon 9 in Ren-2d but is not present 
in either Ren-] allele. The largest insertion is Ml, a 7.2kb sequence flanked by short 
direct repeats found between Ren-2 and Ren-1. 
Significant homology exists between the mouse and rat renin, approximately 
88% and between the mouse and human renin genes, approximately 78%. At the 
amino acid level, all three mouse renin genes exhibit -97% homology. The most 
significant differences are between the Ren- 1 and Ren-2 proteins at three asparagine-
linked glycosylation sites, which may account for the differences in glycosylation and 
thermostability. 
1.5 Angiotensinogen 
Angiotensinogen is a glycoprotein identified in the a-2 globulin fraction of 
plasma. It is the only known substrate for renin and is the precursor of all the 
angiotensin peptides (Lynch et al. 1991). Tissue specificity and hormonal 
responsiveness are controlled by cis-acting elements in the 5' flanking region of the 
gene. Despite different sizes of mRNA being produced by multiple polyadenylation 
sites it does not result in altered substrate specificity. It appears that hormonal stimuli 
and ontogeny affect the choice of polyadenylation site (Ohkubo et al. 1986). 
Angiotensinogen is post-translationally modified by glycosylation resulting in Aos with 
different isoelectric points and molecular weights. These Ao isoforms are all equally 
effective renin substrates (Ohkubo et al. 1986). The functional significance of Ao 
isoforms remains unclear, but one high molecular weight molecule has been postulated 
to associate with hypertension in pregnant women (Lynch et al. 1991; Ward et al. 
1993), and linkage studies demonstrated a correlation between high blood pressure and 
Ao isoforms (Jeunemaitre et al. 1992). 
In adult mammals the greatest source of Ao is the liver, where it is synthesised 
and released constituitively (Lynch et al. 1991). Angiotensinogen has also been shown 
to be expressed in brown and white fat, brain, kidney, adrenal, ovary, testes, vascular 
wall, and heart (Campbell et al. 1984; Stornetta et al. 1988; Ingelfinger et al. 1990). 
The expression of the Ao gene seems to be regulated by a number of physiological and 
pathological conditions. Angiotensinogen mRNA increases with salt depletion, 
estradiol, androgens, mineralocorticoids, thyroxine and All and decreases in response 
to insulin administration (Ellison et al. 1989). Localisation and regulation of Ao in the 
kidney proximal tubular cells suggests that Ao could be released either into the lumen 
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or into the renal interstitium, providing a source of substrate for the intrarenal 
generation of angiotensins (Hunt et al. 1992). 
1.6 Angiotensin-Converting Enzyme 
Angiotensin-converting enzyme is a zinc-containing peptidyl-dipeptidase that 
hydrolyzes carboxyl terminal dipeptides from small peptides (Bernstein et al. 1989). 
Angiotensin-converting enzyme (ACE) cleaves the decapeptide Alto the biologically 
active octapeptide All (Beldent et al. 1993). However, ACE is also capable of 
hydrolysing other substrates, including kinins and is the same enzyme as kininase II 
which degrades bradykinin. Therefore, ACE has a dual function in generating a 
vasoconstrictor and inactivating a vasodilator. The entire ACE protein is encoded by a 
single gene consisting of 26 exons (Bernstein et al. 1988). Differential splicing results 
in 2 mRNA species, which are 4.9 and 4.1kb long and are expressed in the lung and 
the testes respectively. The C-terminus contains hydrophobic amino acids which are 
responsible for the ACE anchorage to the membrane of several cell types, including 
vascular endothelium. The soluble form of ACE found in plasma and seminal fluid is 
thought to be derived from the membrane bound enzyme after cleavage of its 
extracellular domain from the cell surface. 
Angiotensin-converting enzyme has been detected in almost all vascular 
endothelium tested (Caldwell et al. 1976). It is also present in the brush border of the 
proximal tubule, small intestine and choroid plexus (Bruneval et al. 1986). These sites 
suggest a role for ACE in water and solute adsorption and possibly degradation of 
small peptides. The location of ACE on the endothelial surface makes it strategically 
positioned for the generation of All and the regulation of systemic vascular tone. In the 
kidney, ACE is located in the endothelium of arterioles, proximal tubules and 
glomerular capillaries. 
The gene expression of ACE is enhanced by cAMP, glucocorticoids and 
thyroxine and may be down regulated by All. Genetic studies in humans indicate that 
ACE variants are involved in cardiovascular pathology. A deletion polymorphism in 
the ACE gene may increase the risk of myocardial infarction (Cambien et al. 1992). 
1.7 The Angiotensin II Receptors 
The angiotensin II receptors are distinguished by their physiological role and 
mode of inhibition. AT  is inhibited by Losartan, DTT and mediates the pressor effects 
	
of All (Bumpus et al. 1991). AT2 is inhibited by the non-peptide PD 12377 and its 	
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structural analogues. The physiological role for AT2 has yet to be defined. The most 
common source for membranes for All binding was the adrenal cortex, recognised as 
containing a mixture of the receptor types (Chiu et al. 1989; Whitebread et al. 1989). 
Autoradiography studies of the adrenal gland demonstrated the heterogeneity of AT 
receptors in the cortex and a relatively pure population of AT2 sites in the rat adrenal 
medulla (Chiu et al. 1989). In the rat kidney only the AT1 receptor is reported (Chang 
et al. 1991; Edwards et al. 1992). In contrast, the human kidney shows a unique 
distribution in which AT2 sites are present on the large preglomerular vessels of the 
renal cortex (Grone et al. 1992). 
The type 1 receptor 	i) belongs to the class of G-protein-coupled seven 
transmembrane receptors (Bunkenburg et al. 1991; Iwai et al. 1991). The receptor 
protein is 359 amino acids long. The native protein is probably subject to post- 
translational modification, with multiple potential N-glycosylation sites found in the 
extracellular domains (Sasaki et al. 1991; Iwai et al. 1992). In the rat two different 
receptor subtypes, type la and lB, have been identified. Sequence comparison 
between these two subtypes shows a high degree of homology (94%) at the protein 
level. Most changes are highly conservative particularly in the transmembrane regions. 
By interacting with specific receptors All elicits multiple cellular responses. The 
coupling of the receptors involves a number of second-messenger systems. 
Angiotensin II stimulates phospholipase C (through a G-protein), the production of 
inositol 1, 4, 5-trisphosphate, diacyiglycerol and the mobilisation of intracellular Ca2 
(Griendling et al. 1989; Griendling et al. 1989). Angiotensin II also stimulates 
phospholipase A2 or D leading to the release of arachidonic acid and its metabolites 
(Ford et al. 1989). Recently, it has been demonstrated the All, through the AT1 
receptor, stimulates the Jak/STAT pathway (Marrero et al. 1995). Jak2 appears to 
associate intimately with the AT I receptor indicating that Jak2 activation in response to 
ligand occupancy of the AT1 receptor is analogous to cytokine receptor activation. 
Angiotensin II has been shown to promote growth of smooth muscle cells and to 
induce proto-oncogenes such as c-fos (Geisterfer et al. 1988). It has been proposed in 
other cell types that the Jak/STAT pathway is used by cell surface binding cytokines 
responsible for transcriptional activation of early growth-response genes (Darnell et al. 
1994). It is possible that the Jak/STAT pathway may play a similar role in the control 
of All-mediated cell growth (Marrero et al. 1995). 
1.8 Tissue Renin-Angiotensin Systems 
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The presence of renin activity mt he blood vessesi walls was demonstrated by 
Gould et al in 1964. Since then the possibilty that there exists, outwith the circulating 
renal-derived RAS, tissue RASs in several tissues has provoked continued interest. 
These tissue RASs may have complementary and distinct functions from the classical, 
endocrine RAS. Locally synthesised vascular and cardiac tissue renin has been 
proposed in a number of biochemical and physiological reports (Dzau 1987; Dzau et al. 
1987; Lindpaintner et al. 1991). 
Other members of the RAS are produced, or present is a number of tissues. The 
production of hepatic angiotensinogen results in a relatively constant high level of renin 
substrate, close to Km (half maximal velocity), in both intravascular and extravascular 
compartments. As previously mentioned, the angiotensinogen gene is also expressed 
in several tissues including the heart and kidneys (Stornetta et al. 1988; Ingelfinger et 
al. 1990). Converting enzyme is present in high concentrations in blood and interstitial 
fluid and systemic vascular endothelial cells. 
Conversely, circulating renin levels are exquisitely regulated and subject to 
constant feedback mechanisms (Laragh et al. 1990). The kidneys are the only organs 
which have a demonstrated capacity to synthesise and process prorenin to active renin 
and to secrete renin into the circulation. Other tissues, such as the adrenal and the 
pituitary are capable of producing prorenin protein, but do not secrete active renin into 
the circulation. 
There is no evidence that circulating renin is selectively taken up by any tissue 
other than the liver (Kim et al. 1987). Prorenin constitiutes the vast majority of 
circulating renin yet there is no evidence that it is irreversibly converted, in any 
substantial amount, to active renin in any tissue (Nielsen et al. 1988). An hypothesis 
has been put forward by Sealey et at, however, that prorenincould be reversibly 
activated on binding to a specific receptor that would ensure prorenin remained in an 
"open" conformation allowing it to cleave Al from angiotensinogen (Sealey et al. 
1989). Despite this intriguing possibility there is no evidence of a prorenin binding 
protein or of any physiological reversible activation of prorenin. 
The mode of action through which a vascular RASs may raise blood pressure has 
provoked several proposals. Most interest has focussed of the role vascular RAS has 
in determining vascular structure. Changes in resistance vessel structure, specifically a 
decrease in lumen to wall ratio could be a factor in chronically maintaining increased 
vascular resistance in hypertension (Folkow 1982). 
There remains controversy over whether the heart and vasculature are examples 	
23 
of tissues with localised renin gene expression. Renin mRNA has been detected in 
these tissues in certain studies. If this were the case, these organs may be regulated by 
this local renin. If not, circulating renin would be the only determinant of Ang I 
production in the heart and vasculature. The analysis of studies proved problematical 
due to a number of considerations such as uptake of renin from the circulation and 
renin assay specificity. However, both local synthesis and uptake from circulation may 
be important mechanisms in tissue-specific RASs. 
Unger et al (Dorer et al. 1978; Unger et al. 1985; Unger et al. 1989) found 
marked inhibition of ACE activity in the lung, kidney, aortic wall and myocardium, as 
well as in plasma following oral administration of ACE inhibitors to SHRs. Treatment 
was discontinued after two weeks and plasma ACE activity promptly returned to 
pretreatment levels, whereas blood pressure remained low for 2-3 weeks following 
discontinuation of the ACE inhibitors. The lack of correlation of BP level with plasma 
ACE activity was not seen with tissue ACE activity, especially in the kidney, brain and 
aorta which were more closely correlated with blood pressure response. Assad and 
Antonaccio (Asaad et al. 1982) demonstrated that bilateral nephrectomy virtually 
eliminated plasma renin activity without reducing arterial renin concentrations over a 24 
hour period after nephrectomy in both SHRs and Wistar-Kyoto rats. The SHR 
showed a higher arterial renin concentration than that found in the Wistar-Kyoto rat and 
after bilateral nephrectomy Captopril still exerted an antihypertensive effect. Vascular 
renin, therefore, may respond to inhibition by Captopril and may be responsible for 
some of the increase in blood pressure level seen in the SHR. 
Owens (Owens 1985) treated SHRs with either hydraliazine or Captopril at doses 
that gave equal blood pressure reduction. Smooth muscle mass was decreased with 
Captopril relative to hydrazine, suggesting a non-pressure related factor, possibly Ang 
II, may be an important mediator of smooth muscle cell growth. Captopril also 
significantly reduced smooth muscle cell size in the Wistar-Kyota control rat, 
suggesting an Ang II role in smooth muscle cell growth in this normotensive strain. 
As previously mentioned, Ang II also affects growth and gene induction in 
cultured cardiomyocytes and may play an important role in various disease processes in 
the heart as well as in the vessel wall. After demonstration by Pfeffer et al (Pfeffer et 
al. 1985) that ACE inhibitors prevent ventricular remodelling in rats after experimental 
myocardial infarction, groups in Boston (Pfeffer et al. 1988) and New Zealand (Sharpe 
et al. 1988) demonstrated that treatment with ACE inhibitors, following myocardial 
infarctions in humans, resulted in an increase in systolic volume index and an 
improvement in ejection fraction in both studies. 
Although tissue RAS components may be either of local or circulating origin, 
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these local compartments may generate Ang II with different enzyme-substrate 
concentrations and kinetics. Although circulating RAS is important for regulation of 
the cardiovascular system, in individual tissues production of Ang II can be altered by 
local activation of tissue ACE, which may not necessarily result in a systemic blood 
pressure effect but could result in altered local function such as cardiac and vascular 
remodelling and artherosclerosis. 
1.9 Transgenesis 
A transgene can be defined as a sequence of DNA introduced into a species by 
one of a number of methods. Following stable chromosomal integration, the transgene 
is transmitted through the germ line by Mendelian inheritance to subsequent generations 
(Hogan et al. 1986; Lang et al. 1994). Due to experimental constraints most transgenic 
animal work has been done in mice and more recently in rats. Transgenesis can be 
achieved in rabbits at a lower efficiency and with difficulty in sheep, goat, pig and 
cow, reviewed by Mullins and Mullins (Mullins et al. 1993). The effects of 
manipulating an individual gene, within a complex system, and the subsequent genetic 
and environmental interactions giving rise to the resulting phenotype can then be 
studied in vivo. 
The genetic material forming the transgene construct may consist of DNA from 
the same species or from a different species. The promoter sequence of the gene of 
interest can be used to direct appropriate tissue specific and temporal expression. 
However, an heterologous promoter can be used to direct expression of a transgene to 
specific tissues, or allow expression to be stimulated in response to a defined stimulus. 
For example the metallothionein promoters can respond to dietary heavy metals 
mediated by heavy metal sensitive response elements within the promoter sequence 
(Yiangou et al. 1991). This can circumvent problems of transgene expression during 
foetal development or allow the study of the effects of transgene function starting at a 
defined time point. Regulatory elements within promoter sequences of genes can be 
studied using 'reporter' gene constructs where a promoter sequence is linked to a gene 
encoding an easily detectable enzyme (Hunter et al. 1993; von Harsdorf et al. 1993). 
These may be designed to express either a conveniently assayable product, e.g. the 
Escherichia coli Lac Z gene codes for b-galactosidase which produces a blue colour on 
cleavage of the substrate X-gal (5-bromo-4-chloro-3 -indolyl-b-D-galactosidase), and 
the green fluorescent protein (Prascher et al. 1992; Chalfie et al. 1994). Another 
marker of gene expression used is SV40 which by production of T antigen leads to 
tumourigenesis (Sigmund et al. 1991). A series of constructs with systematic deletions 
	25 
of putative regulatory regions within promoter sequences ligated to the reporter gene 
enables identification of the specific sequences which are important for determining 
regulation of gene expression (Sigmund 1993). 
The structure of the transgene makes an important contribution to the level and 
specificity of its expression. Locus control regions (LCRs) (Needham et al. 1992; 
Strouboulis et al. 1992), matrix attachment regions (MARs) (Stief et al. 1989) and co-
integration strategies add to the level of complexitity in applying transgenic technology. 
Both LCRs and MARs serve to insulate the transgene from any silencing effects seen in 
a region of integration and give position and copy-number independent gene 
expression. Often large constructs can be assembled by co-injection in vivo but it is 
preferable to manipulate genomic transgenes. This may ultimately take the form of 
artificial mammalian chromosomes, however presently transgenic animals have been 
produced using yeast artificial chromosomes (Montoliu et al. 1994). 
For experiments that require large numbers of preimplantation embryos, such as 
microinjection of eggs, gonadotrophins are often administered to females prior to 
mating to increase the number of eggs that are ovulated (superovulation). Pregnant 
mare serum (PMS) is used containing follicle-stimulating hormone (FSH) and human 
chorionic gonadotrophin (hCG) containing luteinizing hormone (LH) is also used. The 
efficient induction of superovulation depends on several variables: the age and weight 
of the females, the doses of gonadotrophins and their time of administration, and the 
strain used. 
Fertilised eggs can be collected several hours before microinjection. Once the 
oviducts are removed from the mated females they are placed in an embryological 
watch glass containing M2 medium (see table 2.1) at room temperature. The newly 
ovulated oocytes 
(-V 
12 hours postovulation), surrounded by cumulus cells are found in 
the ampulla, the upper region of the oviduct. The oviduct is opened in M2 medium 
(see table 2.1) containing 300mg/mi hyaluronidase (Calbiochem) and incubated at room 
temperature for several minutes until the cumulus cells fall off. M16 medium is 
dispensed in 30t1 drops on the bottom of a 35-mm sterile plastic tissue culture dish. 
Sterile pipettes are used to transfer the embryos into the drops of M16 medium and the 
dishes are placed in a 37°C, 5% CO2 incubator. 
The pronuclei of fertilised eggs can be most easily be injected when they are at 
their maximum size. The pronuclei swell progressively during the one-cell stage and 
are at an optimal state for injection for a period of 3-5 hours. An oocyte is prepared for 
injection by placing the tip of the holding pipette next to the oocyte and applying 
negative pressure through the holding pipette to keep the egg attached to the holding 
pipette (see figure 3.2). The pronuclei are located under the microscope and ideally it 
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should be in the hemisphere of the egg closest to the injection pipette, central to the axis 
of the holding pipette. Either male or female pronuclei may be injected, however, the 
male pronucleous is usually larger and easier to "hit'. 
	
zona peI1ucida 	....... 	polar body 





Injection of the pronucleus. The plasma membrane has been pierced and the egg returns 
to a spherical shape. 
The zona pellucida of a fertilised rat egg is much more resilient than the mouse 
counterpart. This leads to problems in piercing the egg during injection. Typically 50-
60% of the eggs survive the injection and they are then transferred into the oviduct of a 
0.5 p.c. pseudopregnant female (see table 3.1). 
Vasectomized or genetically sterile males are used to produce pseudopregnant 
females for oviduct transfer. After females in oestrus are mated with sterile males, the 
female reproductive tract becomes receptive for transferred embryos, despite her own 
unfertilised eggs degenerating. A pseudopregnant female will not resume her natural 
cycle for approximately 11 days. 
The fertilised eggs are then removed, separated from surrounding cumulus cells 
by enzymatic digestion with hyaluronidase (Cal Biochem), 1U in 2.5 ml M2 media, 
and maintained in culture medium in a CO2 incubator at 37°C. When the pronuclei are 
visible, microinjection of the DNA construct (1 mg/ml) is performed using a glass 
holding pipette and microinjection needle (<1 mm diameter) and approximately 2 p1 of 
DNA solution is introduced, usually into the larger male pronucleus (see Chapter 3, 
figure 3.2). Fertilized eggs surviving this process are reimplanted into the oviducts of 
pseudopregnant females (mated with vasectomized males) and a variable proportion of 
the progeny born will then carry the transgene (Lang et al. 1994). 
The transgene construct is first linearised by restriction enzyme digest which then 	
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forms concatamers of DNA and randomly integrates into the genome of the recipient. 
Integration is tested by Southern blot hybridisation and analysis of tail DNA from the 
resulting progeny using a transgene specific sequence as the probe or, alternatively, by 
polymerase chain reaction (PCR) using transgene specific sequences for primers. 
Multiple integration events can occur and this can be assessed by diagnostic Southern 
blot hybridisation. Integration may disrupt endogenous gene sequences or function, 
and hence any phenotype observed in transgene positive (TG+) animals must arise in 
more than one TG+ littermate to be certain that an insertional mutagenic effect is not 
responsible (Jaenisch 1988). 
Expression of the transgene is then assessed by detecting mRNA by Northern 
blot analysis and in situ hybridisation determining both tissue distribution and temporal 
patterns of expression. The protein product or other intermediate phenotypes can be 
quantified and the resulting phenotype characterised. Breeding strategies can be 
developed to obtain animals homozygous for the transgene, segregate multiple insertion 
events or by crossing with a different transgenic line a new transgene can be introduced 
to create a double transgenic (Ornitz et al. 1991). The species into which the transgene 
is introduced may directly influence transgene expression. For example strain specific 
modifiers may affect transgene methylation and hence expression and phenotype 
(Boyes et al. 1991; Bird 1992). 
Recent techniques for inhibiting or abolishing endogenous gene function have 
been developed. Selective inactivation or mutation of a targeted gene can be performed 
in vitro by homologous recombination in embryonic stem (ES) cells (Capecchi 1990; 
Doetschman et al. 1993). The gene of interest is interrupted by the introduction of a 
homologous sequence carrying a selectable marker, usually sequences which confer 
antibiotic resistance. Genetically altered ES cells carrying the mutation are then selected 
for by resistance to the relevant antibiotic, e.g. neomycin, in culture and are then 
introduced into a blastocyst. Resulting progeny will be chimaeric with coat colour 
being used to identify the relevant ES cell origin and confirm germ-line transmission of 
the mutated gene in subsequent generations. Gene knock-out technology and 
phenotype analysis are limited at present by the ability to culture ES cells only in certain 
strains of mice, predominantly mouse strain 129. Targeted disruption can be lethal 
during embryogenesis, but results of such studies are identifying new roles for some 
genes in development and apparent functional redundancy of others (Kessel et al. 1990; 
Chisaka 1991; Wright et al. 1991). 
1.10 RAS Transgenics 
	 NM 
Initial experiments using transgenesis in the RAS focused on generating a 
phenocopy of 2-renin gene mice, using a genetic background containing a single renin 
gene (Ren- Ic) and a transgene consisting of the duplicated renin locus (Ren-2). Both 
Tronik et at (Tronik et al. 1987) and Mullins et al (Mullins et al. 1988) reported such 
models using different background strains, genetic origin of transgene and extent of 
transgene sequence used (2.5kb and 5.3kb of 5' flanking sequence respectively). The 
tissue-specific expression of the renin transgene differed in the two reports. Tronik et 
at reported qualitatively correct expression whereas Mullins et al reported low 
expression in some tissues yet elevated in others. These studies both observed that the 
transgenes used were hormonally regulated in the appropriate target tissues. 
To assess more directly the location of important transcriptionally regulatory 
elements controlling mouse renin expression, transgenic mice were generated with 
constructs consisting of the mouse Ren-2 promoter fused to the SV 40T antigen gene 
(Sola et al. 1989; Sigmund et al. 1990). Despite containing the same sequence as 
employed by Tronik et al inappropriate tissue-specific expression was observed and 
neither the tissues nor the tumours expressed renin endogenously. This suggested that 
the proximal 2.5kb of 5' flanking information was insufficient to direct expression of a 
reporter gene to renin expressing tissues in vivo. 
Sigmund et al went on to generate transgenic mice with a construct containing 
4.6kb of Ren-2 5' flanking sequence which exhibited qualitative tissue and cell specific 
expression (Sigmund et al. 1990). The transgene was also hormonally regulated in the 
submandibular gland, followed the normal developmental profile as the renin gene in 
the kidney and was responsive to the effects of angiotensin converting enzyme 
inhibitors during early postnatal life (Sigmund et al. 1991). These results suggest that 
important transcriptional regulatory elements lie between 2.5kb and 4.6kb, it does not 
rule out the possibility that redundant elements lie 3' of the gene or within the gene 
itself. 
As with the mouse system, studies on human renin hRen expression began with 
large genomic clones. Both Fukamizu et at (Fukamizu et al. 1989) and Seo et at (Seo 
et al. 1990) first reported the tissue-specific expression of one hRen transgenic line, 
which contain the entire coding region and 3.0 and 1.2kb of 5' and 3' flanking 
sequences, respectively. 
1. 11 Trans genic Mouse Models of Hypertension 	
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Initially studies into the genetic determinants of hypertension were limited to 
candidate genes. Polymorphisms in genes expected to be involved in hypertension 
were examined to determine if they cosegregated with an increase in blood pressure in 
F2 cohorts derived from hypertensive and normotensive strains. From these studies, 
renin was suggested to be linked to hypertension in some, but not all, hypertensive rat 
strains. To test the hypothesis that the renin-angiotensin system may be linked to the 
pathogenesis of hypertension, Ohkubo et at (Ohkubo et al. 1990) studied the result on 
blood pressure of elevated synthesis and release of components of the renin-
angiotensin system. Two constructs were designed with expression of both the rat 
renin (rRen) and rat angiotensinogen (rAng) under the control of the mouse 
metallothionein (MT) I promoter. As the MT promoter is active in liver and is 
responsive to heavy metals such as zinc the aim of the experiment was to constituitively 
release the proteins into the circulation and examine the physiological effects. 
Transgenic mice were created containing either the rat renin (MT-rRen) or rat 
angiotensinogen (MT-rAng) and crossed to produce transgenic lines carrying both 
transgenes. 
Systolic blood pressure was unchanged in any of the single transgenics 
compared with age matched nontransgenic littermates. Systolic blood pressure in the 
doubly transgenic males and females was increased by 30.5 mmHg and 25.2 mmHg 
respectively as compared with nontransgenic littermates. The increase in systolic blood 
pressure was reduced to normal levels, as anticipated, after treatment with Captopril. 
These results point out an important feature of the enzymatic interaction between renin 
and its substrate, namely it is species specific. 
An analogous experiment to that of Ohkubo et al was carried out by Kimura et al 
(Kimura et al. 1992) generating transgenic mice containing the entire rat 
angiotensinogen, but not the rat renin gene. In some cases these singly transgenic 
exhibited a sustained increase in mean arterial pressure despite the absence of the rRen 
gene. The differences in design of this study as opposed to Ohkubo et at were 1) 
Kimura et at used a genomic rAng gene and 2.5 kb of flanking sequence, 2) the method 
of measuring blood pressure was performed by chronic intra-arterial catheter in 
conscious mice instead of tail cuff plethysmography employed by Ohkubo et at and 3) 
the level of rAng was twice that seen in the MT-rAng transgenic mice. 
The species specificity of renin for its substrate was examined by Fukamizu et at 
by using recombinant mouse SMG renin and recombinant human renin with mouse 
liver extract as the substrate. It was demonstrated the human recombinant renin had a 
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2.5 fold lower Km and 23 fold lower Kcat than the mouse renin. This suggests that 
mouse angiotensinogen is not a suitable substrate for human renin. Fukamizu et al then 
examined transgenic mice containing the human renin and angiotensinogen genes 
(Fukamizu et al. 1993). As with the transgenic models containing both rat renin and 
angiotensinogen genes, the singly transgenic mice showed normal blood pressures 
whereas the doubly transgenic mice showed a sustained increase of 30 mmHg in 
systolic blood pressure. Despite all experimental groups showing a decrease in systolic 
blood pressure after administration of an ACE inhibitor only the doubly transgenic mice 
demonstrated a decrease with a human specific inhibitor. 
1. 12 Transgenic Rat Models of Hypertension. 
Cardiovascular research has historically been carried out on animals larger than 
mice such as rats, rabbits and sheep. Despite techniques for measuring detailed 
physiology in mice improving there has been a great deal of interest in generating 
transgenic species of larger animals. The first rat model of hypertension was created 
by Mullins et al using the entire mouse Ren-2 gene (Mullins et al. 1990). The 24 kb 
Xho- 1 fragment of mouse genomic DNA containing the Ren-2d gene as described 
above (Mullins et al. 1988) was microinjected into fertilised TG1 oocytes of a Sprague-
Dawley/WKY cross. Thirty-seven eggs were re-implanted and eight progeny were 
delivered. By Southern blot hybridisation five were transgene positive (TG+), of 
which three (founders #25, #26, and #27) transmitted the transgene to the next 
generation. Four of the five TG+ founders were found to be hypertensive with 
SBP>.200 mmHg by ten weeks of age confirming a transgene position-independent 
phenotype (Mullins et al. 1990). The normotensive TG+ founder #26 was found to be 
mosaic for the transgene, however, inheritance of the transgene in her offspring was 
associated with blood pressure elevation comparable to the other positive founders. 
Significant hypertension was sustained in subsequent generations in two lines, #26 and 
#27, though male infertility in line #26, a probable consequence of transgene 
insertional mutagenesis, prevented the subsequent generation of homozygotes in this 
line. The line TGR(mRen-2)27 as derived from founder #27 which has now been the 
subject of extensive investigation into detailed characterisation of the phenotype and the 
cause of the hypertension seen in these animals (Peters et al. 1991; Bachmann et al. 
1992; Peters et al. 1993; Tokita et al. 1994; Vettor et al. 1994; Yasuo 1994). 
Serial measurements of SBP by tail cuff plethysmography of TGR(mRen-2)27 
rats (hemizygous for the transgene) showed an increasing blood pressure with age, 
attaining a plateau at nine to ten weeks. Initial characterisation of the phenotype 	
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showed high plasma prorenin, and elevated adrenal tissue renin content (Mullins et al. 
1990). Adrenalectomy with maintenance therapy of oral NaCl resulted in a fall in 
plasma prorenin to transgene negative (TG-) levels together with a fall in SBP 
suggesting that the adrenal was the principal source of the high circulating prorenin 
(Bachmann et al. 1992). In situ hybridisation and immunohistochemistry of the 
adrenal gland showed both over-expression of the mouse Ren-2 transgene and renin 
protein to be principally present in the zona glomerulosa and outer zona fasciculata. 
Northern blot and ribonuclease (RNase) protection assays also identified high 
transgene mRNA transcripts in the adrenal gland, -'-2500 fold higher than endogenous 
rat renin gene expression, and between 10 and 500 fold higher expression in this tissue 
compared with any other tissues assayed (Peters et al. 1991). Expression of the 
transgene in adrenal tissue, as shown by Ren-2 mRNA levels was high from birth and 
progressively increased with age (Zhao et al. 1993). 
Transgene expression in the kidney however, was highest at birth and decreased 
markedly at two to four weeks of age with further reductions occurring with 
developing hypertension. A similar profile was seen for endogenous rat renin 
expression with evident suppression in adult TGR compared to SD controls (Zhao et 
al. 1993). Suppressed kidney tissue renin and PRA was seen in TG+ compared to 
TG- littermates (Mullins et al. 1990). 
Detectable transcripts were also found in brain (cortex/septum), pituitary, aorta, 
mesenteric vessels, lung, testes, ovary, coagulation gland, thymus, small intestine, 
stomach and uterus, all being sites of normal Ren-2 expression in the mouse. 
However, Ren-2 expression was not found in the rat SMG gland suggesting an 
absence of necessary trans acting factors. Other notable sites of absent expression as 
determined by Northern hybridisation included liver, heart, parotid gland, spleen and 
cerebellum (Peters et al. 1991). Others have reported Ren-2 mRNA in the heart by 
RNase protection assay at the limits of detection (Zhao et al. 1993). In TG- controls, 
using a Ren-2 derived probe that hybridised to rat renin mRNA, endogenous rat renin 
gene expression has been only detected in the kidney (Peters et al. 1991), but others 
have reported low levels of expression in adrenal, brain, pituitary and thyroid by 
RNase protection assay (Zhao et al. 1993). 
The underlying cause of hypertension in the TGR(mRen-2)27 rat line is yet to be 
elucidated. Interest has focused on the adrenal gland in view of the high transgene 
expression and concomitant elevation of adrenal tissue renin and prorenin which were 
predominantly transgene derived, while renal tissue renin and plasma renin reportedly 
remained suppressed (Yamaguchi et al. 1992; Peters et al. 1993). In association with 
the elevated adrenal transgene expression, mineralocorticoid levels were altered with 
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increased 24 hour urinary excretion rates for 18-OH cortisol, deoxycorticosterone 
(DOG) and aldosterone in TG+ rats from six to eighteen weeks of age, but not at thirty 
weeks, compared with age matched SD rats. Conflicting results were found for plasma 
measurements with decreased DOG, in both transgenic homozygotes and hemizygotes 
compared to SD controls while plasma corticosterone levels were similar in SD and 
transgenic homozygotes but were significantly elevated in hemizygotes. No significant 
differences were observed for either plasma sodium or potassium levels in the three 
groups (Sander et al. 1992). Electron microscopy of adrenal tissue has revealed 
evidence of cholesterol accumulation in zona glomerulosa (ZG) cells. Studies on 
dispersed ZG cells from female transgenics showed a higher basal aldosterone 
secretion compared to cells from SD rats, but no difference between transgenics and 
controls in the net increase in aldosterone release in response to either Ang H or ACTH 
(adrenocorticotrophic hormone) stimulation was found (Rocco et al. 1994). 
An increase in active renin release, from cultured adrenal cells from transgenic 
rats was seen in response to both Ang II and raised intracellular Ca2 (Peters et al. 
1993). Such mediators would normally be expected to elicit a negative feedback 
response on the kidney, suggesting that the normal negative feedback control does not 
operate on cultured adrenal cells derived from TG+ animals. Prorenin release in vivo 
was clearly stimulated by ACTH with a 10-fold rise in plasma levels compared with 
only a 4-fold rise in non-transgenics. However plasma renin concentration remained 
unaffected or fell respectively (Sander et al. 1992). If transgene expression in the 
adrenal does lead to deranged mineralocorticoid synthesis and metabolism, it seems 
unlikely that it is the sole factor inducing hypertension as spironolactone therapy did 
not lower blood pressure or prevent the development of high blood pressure in TG+ 
rats despite treatment leading to an elevation of plasma renin concentration in both SD 
and TG+ animals (Bader et al. 1992; Sander et al. 1992). 
Measurement of free intracellular sodium in intact lymphocytes from 
TGR(mRen-2)27 using a sodium sensitive fluorescent dye method showed an increase 
relative to SD. This appeared to be secondary to reduced Na+K+ATPase  activity 
measured in erythrocytes, which also argued against a mineralocorticoid mediated 
effect (Tepel et al. 1994). It was not however established as to whether the animals 
studied had established hypertension or were pre-hypertensive. Dexamethasone 
suppression of pre-hypertensive TGR(mRen-2)27 did attenuate the BP rise, with a 
concomitant rise in mineralocorticoid levels, but a fall in plasma glucocorticoids (D. 
Ganten, unpublished observations) [Springate, 1994 #5261. 
No evidence of increased insulin resistance in TGR(mRen-2)27 hemizygotes has 	
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been demonstrated as shown by similar fasting plasma glucose and insulin levels 
together with equivalent fasting rates of hepatic glucose production and glucose 
utilisation during a hyperinsulinaemic euglycaemic clamp (Vettor et al. 1994). 
Aims 
The aims of this project were to: 
Elucidate role of high levels of circulating prorenin in the TGR(mRen-2)27 
rat. 
Express prorenin, at a site distant from the kidney in transgenic rats. 
Validate mouse mRNA and protein expression in the transgenic rats. 
Investigate the phenotype of hypertension, with severe cardiac hypertrophy, 




The chemicals for general work were supplied by either Fisons (Loughborough), 
BDH (Poole) or Sigma (Poole), and were Analytical grade or equivalent. If a particular 
brand of chemical was required, this is noted in the text. Media for bacterial culture 
were supplied by Difco (East Molesley). Radionucleotides were supplied by 
Amersham International (Amersham). Double-distilled water was prepared using the 
PRIMA system from Elga (Bucks). 
Polyacrylamide gels were prepared using the Sequagel reagents, TEMED and 
urea for gel electrophoresis were supplied by Sigma, as was ethidium bromide. 
Hexanucleotides for random priming DNA synthesis were supplied by Pharmacia 
(Milton Keynes). Phenol (containing hydroxyquinoline) was purchased redistilled and 
equilibrated with 10mM Tris-HC1 (pH8.0) from Phi-Bio through Fisons. 
2.2 Enzymes 
Restriction endonucleases were purchased from Boehringer Mannheim, or New 
England Biolabs. T4 polynucleotide kinase was supplied by Gibco-BRL. DNA 
polymerase I (Kienow fragment) was supplied by Amersham International 
(oligolabelling and creating flush ends). T7 DNA polymerase and DNase I were 
supplied by Pharmacia. T4 DNA ligase was purchased from both New England 
Biolabs and Gibco-BRL. Proteinase K was purchased from Boehringer Mannheim 
(Lewes), and ribonuclease A from Sigma. 
2.3 Animals 
Animal husbandry and associated procedures were all performed in accordance 
with the regulations set down by the Animal (Scientific Procedures) Act 1986. All 
animals were housed in the Centre for Genome Research, and were maintained in 
controlled conditions with regulated temperature (18-20°C) and humidity (45-65%). A 
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12:12 hour light/dark cycle was used. Rats were kept with their mothers to three 
weeks of age. At three weeks of age the animals were tail biopsied and weened from 
their mother. It was then that the animals were split, according to sex, into cages of no 
more than four. Founder animals and breeding animals were caged individually, 
except when mating with non-transgenic mates. Special breeding cages were used to 
house pairs of pregnant females that were 2.5 times larger than a standard rat cage. All 
transgenic animals were checked twice daily. Bedding was changed weekly, feed and 
water topped up daily. Standard rat chow (0.32% sodium, CRM diet, SDS Witham, 
Essex, UK) was used. Tap water was provided ad libitum to drink, and captopril was 
administered to the breeding animals (10 mgkg 1 per day) in the water. 
Methods 
2.4 General Methods 
Restriction endonucleases and DNA modifying enzymes were used according to 
the manufacturers' instructions. Other enzymes were used according to published 
protocols, as indicated in the text. All solutions for use with RNA were made up with 
water to which 0.02% (v/v) diethyl pyrocarbonate (DEPC, from Sigma) had been 
added prior to autoclaving. The transcription buffers used in the synthesis of 
riboprobes were an exception to this, as DEPC inhibits T3 and T7 RNA polymerases. 
2.5 Tail DNA Preparation 
After application of local anaesthesia (ethyl chloride B.P. spray), the distal 1 cm 
of tail was cut off pups at weaning and placed immediately in an eppendorf tube on dry 
ice. To the resultant wound tissue adhesive (VetBondTM)  was applied. Tissue obtained 
from tail biopsy was digested overnight in 700p1 of a buffer containing 50mM Tris-
HC1 pH 8.0, 100mM EDTA, 100mM NaCl, 1.0% SDS with 35p1 of 10mg/mi 
proteinase K at 55°C. 700jil of tris-saturated phenol was added and the samples placed 
on a vertical rotator for 15 minutes. Samples were then spun in a microfuge for 5 
minutes to separate the phases and the aqueous phase and interface were transferred to 
fresh 1.5m1 Eppendorf tubes. Phenol/Chloroform/Iso Amyl Alcohol (25:24:1) (700tl) 
was added to each sample and again placed on a vertical rotator for 15 minutes. The 
samples were spun in a microfuge for 5 minutes to separate the phases and the aqueous 
phase and interphase were transferred to fresh 1.5m1 tubes. Chloroformllso Amyl 
Alcohol (24:1) (700 jil) was added and the samples were placed on a vertical rotator for 
15 minutes. The phases were separated by spinning the samples in a microfuge then 
only the aqueous phase was transferred to a fresh tube. Isopropanol was added 700tl 
then the tubes were inverted several times and left at room temperature for 10 minutes. 
The samples were then spun at maximum speed for 10 minutes, the supernatant 
removed and the pellet washed in 70% ethanol. Finally, the samples were spun in a 
microfuge for 5 minutes, the ethanol removed, the pellet allowed to dry briefly and then 
resuspended in 200tl of Tris/EDTA pH8.0 and stored at -20°C. 
92 
2.6 Polymerase Chain Reaction 
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In order to identify transgenic positive animals as soon as possible a diagnostic 
PCR was developed taking advantage of the differences in renin genomic and transgene 
structure. The PCR reaction was carried out using three primers, all 21 -mers, from 
exon 3 (CCATCCCAGACCTTCAAAGTC) exon 6 
(CCTGGCAGATCACCATGAAGG)and exon 7 (GCTCCCTGCAGTTGATCATGC). 
There is a single base mismatch in primers exon 6 and exon 7 to compensate for a 
sequence difference between rat and mouse renin genes. This mismatch allows the 
primers to anneal at the same temperature to both DNA species. As the reaction 
conditions have not been optimised for generation of large PCR products, the exon 3 
primer/exon 7 primer pair did not give rise to a product in the genomic situation. for 
Ren-2 sequence. 





Exon 3 —ftIJJ-Exon 7 
580 bp 
125 bp 
cDNA Transgene Situation 
Figure 2.1 Schematic of diagnostic PCR reactions. See above for details of the PCR 
reaction and the oligonucleotides used. 
Tail DNA, 2.5pJ, was added to 40.5iI of double distilled H20 (Elga autostill) 
and 5p1 lOx Boehringer Mannheim (U.K.) Taq polymerase incubation buffer (Tris-
HC1 100mM, MgCl2 15mM, KC1 500mM, gelatine lmg/ml pH 8.3). To the reaction 
mix 0.5tl of 10mM dNTP and 1.25p.l of each primer (10pM) was added. Finally 
0.25tl of Taq polymerase, Boehringer Mannheim (U.K.) was added with 75tl of light 
white mineral oil, Sigma (U.K.) overlaid. The running conditions were as follows: 
denaturing 94°C for 1 minute, annealing 58°C for 1 minute and extension 72°C for 1.5 
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minutes with thirty cycles of each. A final extension was performed at 72°C for 10 
minutes followed by cooling to 18°C. The products were then resolved on a 2.5% 
agarose gel. 
2.7 Electrophoresis 
Agarose. Plasmid and genomic DNA was analyzed by electrophoresis through 
horizontal agarose slab gels (Seakem LE, NuSieve GTG, both purchased from 
Flowgen, Sittingbourne, Kent), which varied between 0.8% and 4% (w/v). Gels were 
run in 0.5 x TAE (20mM Tris-acetate; 10mM sodium acetate; 0.2mM EDTA, pH 8.3), 
or in 0.5 x TBE (45mM Tris-borate; 45mM boric acid; 1mM EDTA, pH 8.2) unless 
otherwise stated. Similarly, RNA samples were analyzed by agarose gel 
electrophoresis, except tone gel tank was set aside specifically for this purpose. This 
tank was cleaned regularly, treated with 3% H202  and rinsed with DEPC-treated water 
immediately prior to use. 
The choice of size markers used on each gel was dependent upon the sizes of the 
DNA fragments to be resolved, and was one of the following: pUC18 x HpaII; 
bacteriophage ? (Gibco-BRL) x HindHTJEcoRI + Hindu! or X x EcoRV. 
Polyacrylamide. Polyacrylamide gels for resolving the products of RNase 
protection reactions were according to the method of Sanger and Coulson (1978), and 
were 6% polyacrylamide and 8M urea in a 0.5 x TBE to 1 x TBE buffer gradient. An 
alternative to this was the Sequagel Sequencing System (National Diagnostics, Bucks, 
England) where concentrate, buffer and diluent are ready-prepared and mixed in the 
appropriate ratios to produce gels of differing concentrations (typically 5%). 
2.8 Southern DNA Blotting 
Capillary transfer was used to transfer nucleic acids separated by gel 
electrophoresis onto positively charged nylon membranes (Boehringer 1417240). The 
method is based on that of Southern (1975). Gels were 0.8% agarose (Seakem LE) 
and were run in 0.5 x TAE (20mM Tris acetate; 10mM sodium acetate; 0.1mM EDTA, 
pH 8.3) unless otherwise stated in the figure legend. Ethidium bromide was added to 
the buffer to a final concentration of 0.5ig/ml. After visualising the DNA by ultaviolet 
light capillary transfer was set up according to Maniatis (Sambrook et al. 1989). The 
DNA was then cross-linked to the filter by baking the filter at 80°C for 30 minutes. 
2.9 Preparation of plasmid DNA 
2.9.1 Mini preparation of plasmid DNA: 
An overnight imi culture of DH5ct E. coli cells was centrifuged for 15 seconds at 
full speed in an Eppendorf centrifuge. The supernatant was removed and the cell pellet 
resuspended in 10%t1 of lysis solution (lysozyme 2mg/nil, 25mM TMO pH 8.0, 10mM 
EDTA pH 8.0, 1% Glucose), vortexed briefly and left on ice for 5 minutes. To the 
lysis mix 200t1 of alkaline/SDS solution (0.2M NaOH, 1% SDS) was added and again 
left on ice for 5 minutes after a gentle mix. The solution was centrifuged for 2 minutes 
and the supernatant passed through a polyallomer wool plug to remove chromosomal 
DNA into a fresh Eppendorf tube. Cold ethanol (imi) was added to the filtered 
supernatant and the Eppendorf placed in a dry ice/ethanol bath for 5 minutes. The 
samples were centrifuged for 2 minutes and the ethanol removed. The pellet was 
resuspended in 20Otl of Tris-Acetate solution (100mM NaAc pH 4.8, 50mM Tris-HC1 
pH 8.0) and 400j.tl of ethanol. After 5 minutes in a dry ice/ethanol bath the samples 
were microfuged for 2 minutes. The ethanol was removed and l00il of 70% ethanol 
added prior to a further 2 minute centrifugation. After removal of the ethanol the pellet 
was resuspended in 40pJ of H20. 
2.9.2 Maxi preparation of plasmid DNA: 
A SOOml culture was grown in L-Broth and 0.02% Glucose and ampicillin at 
37°C. The cells were centrifuged in an HB 101 rotor and Sartorius RC5 centrifuge at 
6,000rpm for 10 minutes at 4°C. The cell pellet was resuspended in 7.5ml of ice cold 
sucrose solution (25% Sucrose, 50mM Tris-HC1 pH 8.0) and 1.25m1 of lOmg/ml 
lysozyme. The solution was inverted gently and left on ice for 15 minutes. To this 
solution 2.5m1 of 0.5M EDTA pH 8.0 was added and again was mixed gently and left 
on ice for 15 minutes. The solution was transferred to a 50m1 centrifuge tube and 
lOmis of Trito lysis mix (2% Triton, 0.05M Tris-HC1 pH 8.0, 0.0625M EDTA pH 
8.0) added. The tube was inverted and gently mixed then centrifuged in an SS-34 rotor 
at 15,000rpm for 30 minutes at 4°C. After decanting the solution the volume was made 
up to 25m1s with a 1:1 mix of sucrose solution and Triton lysis mix. Cesium chloride 
was added (24g) as was ethidium bromide (912.5il of 10mg/mi) and mixed well at 
room temperature. Beckman ultracentrifuge tubes (42m1s) were used and mineral oil 
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was used to fill the unused space and balance tubes. The sample was spun in an NVT 
	40 
65-1 rotor at 55K for 24 hours at room temperature. The plasmid band was removed 
using a G19 needle and lOmi syringe. The solution was extracted five times with an 
equal volume of isoprepanol saturated with C0C12 saturated TE pH8.0 to remove the 
ethidium bromide. The sample was then passed over a Pharmacia NAP-25 column to 
remove the salt and eluted with 3.0tl of 3M NaAc pH 5.6 at -20°C overnight. The 
sample was then placed in a glass Corex 33m1 centrifuge tube and spun at 15,000rpm 
in the SS-34 rotor and RC5 centrifuge for 30 minutes at 4°C. After removal of the 
ethanol the pellet was washed with 70% ethanol (3mls) and recentrifuged at the 
previous conditions. When the 70% ethanol was removed the DNA was resuspended 
in 500tl of TE pH 8.0. 
2.10 Electroelution of DNA from Gels 
The SalI/I-[indffl fragment containing the entire Ren-2 cDNA was restricted from 
the plasmid palAT/Ren-2 plasmid and electrophoresed to separate it from the plasmid 
DNA for use as a cDNA probe in the analysis of the offspring. 
Gel slices were cut from agarose gels and the DNA eluted using two separate 
methods. 
Samples were loaded into dialysis apparatus as shown (Figure 2.2). The buffer 
(1 x ISCO) used was 0.05M Tris-HCI, 2 x 10 4M EDTA, pH 7.7. The dialysis vessel 
was placed in the Little Blue Tank ensuring the bridge was dry. The gel slice was then 
put into place and the power adjusted to l5mA for 2 hours. The sample was collected 
by reversing the current for 10-15 seconds and then removing the buffer from the large 
well and from the small well level with the mesh. The buffer below the level of the 
mesh was placed into a 1 .Sml Eppendorf tube, phenol:chloroform extracted and ethanol 
precipitated. 
Another method used was to place the excised gel slice into dialysis membrane 
(Medicell International, London), secured at both ends (exclusion limit 1200 Daltons) 
with a minimum volume of electrophoresis buffer (200t1 0.5 xTAE). The dialysis 
membrane was then placed onto a Pharmacia gel tray and into the gel tank. The 
apparatus was run at 75V for 1 hour. The buffer/DNA was then ethanol precipitated 
and the DNA fragment resuspended in a suitable volume of TE pH 8.0. 
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Figure 2.2 
Dialysis apparatus for use with the Little Blue Tank'. Samples were loaded into 
dialysis apparatus as shown above. The buffer (1 x ISCO) used was 0.05M Tris-HCI, 2 
x 10 4M EDTA, pH 7.7. The dialysis vessel was placed in the Little Blue Tank 
ensuring the bridge was dry. The gel slice was then put into place and the power adjusted 
to 15mA for 2 hours. 
2.11 Randomly Primed Probe 
For both Southern blot hybridisation and Northern blot hybridisation, to detect 
the presence of the Ren-2 transgene or Ren-2 transcript, the Sall/HindIll fragment 
(nucleotides 1970-3219) from palATIRen-2 was used (see Chapter 3, figure 3.1A for 
details of the pal AT/Ren-2 plasmid). The method used to radiolabel DNA restriction 
fragments was that of Feinberg and Vogelstein (1990) (Feinberg et al. 1990). An 
initial mix was prepared containing 1il of template DNA (50ng/.t1), 2tl of TE buffer 
pH 8.0 and 1R1  of random primer (bOng/pA) in a screw-cap Eppendorf then heat 
denatured at 100°C for 2 minutes followed by rapid quenching on ice. After a brief 	
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centrifugation, in a bench-top centrifuge, 2jil of oligo labelling buffer (0.5M - Tris-HC1 
pH 6.9, 0.1M MgSO4, 1mM DTT, 1mM dATP, 1mM dTTP, 1mM dGTP), 5jfl of 
32PdCTP (lOj.tCi/p,l), 7.6iil H20, 11.11  of Kienow (5U/jil) and 0.4p1 of BSA 
(10Jig4tl) were added and mixed. The reaction was incubated at room temperature (22-
25°C) overnight and diluted to lOOpi with TE pH 8.0. 
Pharmacia NAP-5 columns were used to remove unincorporated nucleotides 
from the reaction mixture in order to lower background hybridisation on the Southern 
blot. The NAP-5 column was a prepacked disposable column containing Sephadex G-
25 Medium of DNA grade. The columns were equilibrated with lOrnis of 10mM 
NaPO4 pH 6.8 and the sample added to the column in a volume of 500pl of buffer. 
After the sample entered the gel bed the randomly primed probe was eluted with imI of 
buffer. Any oligonucleotides less than 10bps in length are retained in the columns after 
elution. 
The efficiency of incorporation of radiolabelled nucleotide was tested for each 
new aliquot of probe DNA. This was done by pipetting 2.tls of the final probe mix 
(approximately 1/50) onto a 2cm circle of DE8 1 paper (Whatman, Maidstone), and 
Cerenkov counting in a Packard 1600CA Series scintillation counter (Pangborne, 
Berks), both before and after washing off the unincorporated nucleotides with 0.5M 
Na2HPO4. A typical reaction had 80-90% of the labelled nucleotide incorporated into 
high molecular weight DNA, but any probe containing greater than 50% incorporated 
labelled nucleotide was suitable with no further purification without producing any 
significant background interference during hybridisation. 
2.12 Filter Hybridisation 
Prehybridization was for a minimum of 2-3 hours at 65°C in 3 x SSC (1 x SSC is 
150mM sodium chloride; 15mM trisodium citrate, pH 7.0), 5 x Denhardt's solution 
(100 x Denhardt's is 2% (w/v) each Ficoll 400 (Pharmacia); bovine serum albumin 
(fraction V, Sigma); polyvinyl-pyrrolidone), 0.1% (w/v) sodium dodecyl sulphate 
(SDS), 6% (w/v) polyethylene glycol 6000 and 200.tg/ml denatured salmon testis 
DNA (Sigma). 
Hybridization was performed in the same solution, except that the Denhardt's 
was reduced to 2 x concentration, for 16-40 hours at 65°C. Unless otherwise stated, 
25mls of prewarmed hybridization or prehybridization solution was used for each set 
of filters in a sealed Techne hybridisation bottle. 
2.13 RNA Extraction From Tissue 
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This protocol is for the preparation of total cellular RNA, and is modified from 
the method of Noyes et al. (1979) (Noyes et al. 1979). Frozen biopsy tissues were 
taken from liquid nitrogen, suspended in 5mls of TLES [0.2M Tris-HC1 (pH9.0); 
0.1M LiCl; 25mM EDTA; 0.1% SDS], and Smls of phenol: chloroform: iso-arnyl 
alcohol (25:24:1) in a Falcon 2059 tube and immediately homogenised with a Polytron 
homogeniser. The aqueous phase was then immediately overlaid on a caesium chloride 
pad (5.7M CsCl, 0.005M EDTA) and centrifuged in a Beckmann ultracentrifuge (5000 
rpm, 18 hours, 25°C). The purified RNA was ethanol precipitated, air dried, 
redissolved in DEPC treated distilled water and stored at -70°C. 
2.14 Purification of Poly(A) RNA 
Messenger RNA (mRNA) was purified from total RNA using the Oligotex-dT 
system (Qiagen). 250jig of total RNA was incubated with 15il of Oligotex-dT latex 
beads (10% w:v) in a binding buffer of 60mM tris-HC1 (pH 7.5), 3M NaCl and 6mM 
EDTA at 65°C for three minutes. The samples were left at room temperature for ten 
minutes, to allow hybridisation between the oligo (dT)30 linked to the latex particles 
and the poly (A) tail of the mRNA, then centrifuged at 14000 rpm for two minutes. 
The supernatant was removed and the Oligotex-dT beads washed twice in 6001.11 of 
wash buffer (10mM Tris-HC1 (pH 7.5), 150mM NaCl and 1mM EDTA) and respun 
after each wash. The mRNA was then extracted from the Oligotex-dT beads by the 
addition of 2x2Ojil preheated (80°C) elution buffer (5mM Tris-HCI pH 7.5). The poly 
(A) mRNA was then ethanol precipitated and resuspended in the appropriate volume of 
DEPC treated distilled water. 
2.15 Northern RNA Blotting 
This method is modified from Thomas, 1980 (Thomas 1980). The required 
amount of RNA was ethanol precipitated on dry ice for 20 minutes. After centrifuging 
the samples at 14,000 rpm for 15 minutes at 4°C, the supernatant was removed and the 
pellet washed in 70% ethanol then respun at the same speed and temperature but for 5 
minutes. The pellet was then dissolved in 3.7j.tl DEPC H20  and 12.3t1 'Glyoxal mix' 
(1601.11 spectroscopic grade DMSO, 321.11 0.1M NaPO4 : pH 7.0, 54111 deionised 
glyoxal). The samples were then denatured at 50°C for 1 hour and cooled on ice with 
4.tl of RNA loading buffer added (10mM NaPO4; pH 7.0, 50% (v/v) glycerol, 0.4% 
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(w/v) bromophenol blue). 
The RNAs were resolved on a 1.2% (w/v) agarose gel containing 10mM NaPO4. 
The gel was submerged in 10mM NaPO4 and run at a constant current of 2-4mAIcm 
with buffer recirculation. The blotting procedure to transfer RNA onto positively 
charged nylon membrane was as per Southern blotting. 
2.16 RNase Protection 
SP6 	 911 bp Ren2 cDNA 
J—EcoRI—Sac i-J 	 F— Pst 
Acc I 
pSP65 
Figure 2.3 A cartoon representation of the pSLM plasmid used in the preparation of an 
RNA probe (see text below).The Ren2 specific sequence was a 91 lbp Sad I-Pst I 
fragment ligated into pSPG5 [Onoyama et a! JapHeartJ 19781. The plasmid (termed 
pSLM) was linearised with AccI and transcribed with SP6 polymerase to produce a 224 
nucleotide cRNA (Field et al. 1984). 
RNase protection studies (Zinn et al. 1983) used a sequence specific to the 
mouse Ren-2 transcript to determine the tissue specificity of the transgene. The 
riboprobe was produced by transcribing the desired sequence from linearised DNA. 
The 'transcription mix' contained 1 g of linearised DNA, 1.5tl of 0.1M DTT, 0.75j.tl 
of 2mg/mi BSA, 3t1 of ATP/UTP/GTP (10mM each), 0.5tl of RNAsin, 6.25tl [a-
32P] CTP, 1.5tl 10 x Transcription buffer (400mlvITris-HCI pH 7.5, 60mM MgCl, 
20mM Spermidine-HC1) and lil of SP6 polymerase. The reaction was incubated at 
room temperature for 1 hour. The template DNA was then digested by 1 pA of DNAse 
1, incubated at 37°C for 20 minutes. After phenol/chloroform extraction the reaction 
mix was precipitated with NH4Ac/Isopropanol and spun immediately. The supernatant 
was removed and the pellet resuspended in lOOpi of DEPC H20. To ascertain the 
efficiency of the reaction ijil of the probe was Cherenkov counted as per the randomly 
labelled probe protocol. 
The probe was then diluted to ljil = 150,000cpm and lt1 of probe was 
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NaAc/ethanol coprecipitated with the total tissue RNA on dry ice for 20 minutes. The 
pellet was spun down at maximum speed in an Eppendorf centrifuge for 15 minutes, 
then rinsed in 70% ethanol. The 70% ethanol was removed and the damp pellet was 
resuspended in 30tl of RNAse protection hybridisation buffer (RPH buffer, 87% v/v 
deionised formamide, 40mM PIPES pH 6.4, 430mM NaCl, 1mM EDTA). The 
samples were denatured at 85°C for 15 minutes then hybridised at 60°C overnight. 
Each of the samples then had 350p1 of digestion buffer added (8mM Tris-HCl 
pH7.5, 4mM EDTA pH8.0, 0.25M NaCl, 4000U RNAse T1, 240j.ig RNAse A) and 
were incubated at room temperature for 30 minutes. To the digestion buffer sample 
mix was added, 20jil of 10% SDS and 2.5tl of 20mg/mi Proteinase K which was 
incubated at 30°C for 10 minutes. The samples were then phenol/chloroform extracted 
and 5ig of yeast tRNA added before precipitation with ethanol on dry ice for at least 20 
minutes. After centrifugation and the supernatant removed the pellets were washed in 
70% ethanol and respun. The samples were air dried before being resuspended in ipi 
of DEPC H20 and 4pJ of sequencing gel loading buffer. Following denaturation at 
90°C for 10 minutes the samples were placed on ice and loaded onto a 5% 
polyacrylamide gel. 
2.17 Photography 
Gels were photographed with a Polaroid MP4 land camera, using Polaroid Type 
57, Type 667 (positive only)(R. West. Edinburgh). Fixed tissue sections used for 
histology were photographed with an Olympus C-35AD-2 camera and an Olympus 
BHS microscope with PM-lOADS Automatic Photomicrographic System (Olympus, 
London) using Kodak TM colour slide film or Ilford FP4 black and white print film. 
2.18 Autoradiography 
Autoradiography of [32P]-labelled materials was performed at -70°C with 
intensifying screens (or for very short periods at room temperature), with either Kodak 
X-Omat, or Fuji RX X-ray film. RNase protection gels were dried under vacuum 
prior to autoradiographed at -70°C. 
2.19 Phosphoimaging 
	 Iry 
Dried down gels on Whatman 3MM paper and covered in Saran wrap were 
placed in Molecular Dynamics Storage Phosphor Screens, which have the inner surface 
of the cassette plate coated in hydroscopic phospho-crystals. After a variable length of 
time the screens were laser scanned in a Molecular Dynamics phosphoimager and the 
results either quantitated with associated software, stored on optical disc or printed out. 
2.20 Histology 
Paraffin sections were taken by first placing the tissues in 4% formal saline for a 
minimum of 24 hours. The samples were then placed in a Shandon Citadel 2000 
automatic processor where the tissues were successively dehydrated in 70%, 80%, 
90%, & 3x100% ethanols for lh each except for the final 2 ethanols which were 2h. 
The samples were then immersed in xylene three times for lh, 2h and 2h respectively 
and the final stages were two wax baths for 3h and 4h respectively. The final wax bath 
was under vacuum. 
The wax blocks were kept on ice for 30 mins prior to sectioning. The blocks 
were placed in a Shandon microtome and the block adjusted so that the face was flat to 
the blade. Preliminary sectioning at 25tm was used to cut into the sample until the 
desired area was reached. Sectioning was carried out at a maximum of 5jim. Several 
sections produced a strip which was removed from the microtome and placed in a 50°C 
waterbath. The slide was then submerged in the waterbath and the strip of sections 
floated onto it. The slide was then dried before tstaining. 
The slides were then counterstained by rehydrating in 100%, 90%, 80%, 70% 
and 50% ethanol for five minutes each. The slides were then immersed in H20  for five 
minutes and haemallum (Mayer's) BDH, Poole, England for three minutes. The slides 
were then washed in H20  before staining with eosin, Sigma, Poole, England for two 
minutes. After dehydration in 2x95% ethanols for five minutes the slides were placed 
in isopropanol then xylene for five minutes each. The slides were then air dried and 
500p1 of DPX mountant applied and a cover slip placed on top. 
2.21 Immunohistochemistry 
Slides for immunocytochemistry were prepared by baking paraffin sections at 
60°C for 30 minutes. The slides were then layered with 5% goat serum in phosphate 
buffer solution (PBS) for lh followed by aspiration of the goats serum. The first 
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antibody, which is a 'total renin' antibody which cross reacts with mouse and rat renin, 
is then layered on and left overnight in a moist box. After removal of the renin 
antibody, again by aspiration, the slides were washed three times in 2% goat serum in 
PBS. The sections had 3% H202 added in 2% goat serum in PBS for 1 minute. After 
three more washes in 2% goat serum a goat anti-rabbit antibody was applied for 30 
minutes. There were another three washes in 2% goat serum before approximately 
0.2mg of diaminobenzidine tetrahydrochioride is applied and 0.1% H202 is added (See 
Chapter 4, figure 4.2). Once the samples were processed they were counterstained 
with eosin and heamallum as described above. 
2.22 Ligation 
Ligations were performed using T4 DNA ligase (Gibco-BRL) at 20°C for a 
minimum of 16 hours. For cloning small fragments into vectors, a molar excess of 
small fragment (up to 10-fold) was sometimes used, without the production of 
multiple-insert species. For the ligation of blunt-ended DNA fragments, a higher 
concentration of T4 DNA ligase was used (2.5U), and the reaction incubated for longer 
periods (48 hours or more). 
Specific Procedures 
2.23 Blood Recovery and Plasma RAS Determination 
Two methods of blood recovery were employed, dependent on the size of the 
animal. 
1. Cardiac Puncture: To obtain 500t1 of serum, required for the RIA, tail 
bleeding was not appropriate. Three week old animals were lightly anesthetised by 
halothane inhalation and shaved in the left lateral position. A 24G needle, with a 5m1 
syringe attached was inserted through the rib-cage, into the left ventricle of the heart. 
Negative pressure was applied slowly through the syringe and 1 .OmI of whole blood 
was removed. The rat was then humanely sacrificed, still under anesthetic, by cervical 
dislocation. 
2. Retro-Orbital Bleeds: In older, larger, rats sufficient blood could be obtained 	
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by retro-orbital bleeding. Again, animals were lightly anesthetised prior to the 
procedure with halothane. An heparinised microcrit tube was gently worked between 
the eyeball and the lachrymal glands until blood from the optical sinus flowed through 
the microcrit. In this case the animals recovered with no discomfort and could have the 
procedure repeated, after a suitable period to recover from the anesthetic. 
In both cases the blood was collected into a 1 .5m1 Eppendorf tube containing 
350.tl of inhibitor mix (0.25mM 1.10 0-phenanthraline, 1mM EDTA) and centrifuged 
immediately, at maximum speed for 5 minutes in a benchtop centrifuge. The serum 
was decanted into a fresh tube and frozen at -70°C until required for the RIA. 
Total renin concentration was measured by activating a 10tl aliquot of plasma 
with lOpi of trypsin solution (400 units/ml trypsin, dissolved in TES buffer (0. 1M N-
Tris(hydroxymethyl)methyl-2-aminoethane-sulfonic acid; pH 7.2, 0.01% neomycin, 
10mM EDTA)). Samples were incubated on ice for 10 minutes and trypsin-activation 
stopped by the addition of 5i1 of egg white trypsin inhibitor (1600 units/ml, in TES 
buffer). Plasma active renin was measured by the addition of lOpJ of TES buffer 
(without trypsin) to 10tl of plasma. Each sample was split into three aliquots before 
incubating each with radioactively labelled lyophilised renin substrate (1 25j. 
angiotensinogen), isolated from nephrectomised rat plasma (final concentration; 
80mg/ml, 0.11% 2,3-dimercapto- 1 -propanol, 1.1 Smg/ml 8-hydroxychinolin in TES 
buffer). Reactions proceeded for 1-3 hours at 37°C and were stopped with RIA buffer 
(0.1M Tris-acetate; pH 7.4). The Ang I generated was measured by 
radioimmunoassay (Schelling et al. 1980; Hermann et al. 1988). Three measurements 
for each plasma were then averaged (for each assay) and if reactions and readings 
worked properly an error of ±5% was expected. Plasma prorenin concentration was 
determined as the difference between total renin concentration and plasma active renin 
concentration. Statistical significance was assessed using a Wilcoxon rank test and 
results are given as the mean ±1 SD. 
To determine the contribution of mouse renin to the sum of mouse and rat renin, 
the samples were incubated for 2h at 4°C with a monoclonal antirenin antibody 
(No. 120), which was found to be specific for murine renin with <3% cross-reactivity 
to purified rat renin (Peters et al. 1993). The incubation buffer was 0.1M Tris-acetate 
buffer pH 8.1. Incubation with antibody-free buffer served as a control. 
Antibody/renin complexes were precipitated with formalin fixed Staphylococcus aureus 
protein A. The renin activities were determined before the procedure and in the 
supernatant after immunoprecipitation. 
Ang I and Ang II peptides were extracted from plasma with an equal volume of 	
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an acetone, 1M HCl and water mix (40/1/15 by volume). Samples were centrifuged 
(6,000 x g, 4°C, 10 mm) and the pellet re-extracted with the same volume of the 
extraction medium and re-centrifuged. The supernatants were pooled, the acetone 
removed at 40°C in a stream of air, and the remaining aqueous phase was frozen and 
lyophilised. The dried samples were redissolved in imi of imIVI HC1, and centrifuged 
(10,000 x g, 4°C, 5mm) before radioimmunological measurement of Al and All. 
Ang I and Ang II were iodinated by the Chloramine T method of Greenwood and 
Hunter (1963), and the 1251-labelled angiotensins were purified on a 200 x 10mm 
plastic column packed with DEAE-Sephadex A 25 (Sigma). Antibodies were raised in 
New Zealand White rabbits immunised with angiotensin that had been coupled to 
bovine serum albumin by the carbodiimide method. Ang I and Ang II antibodies were 
used in the RIA in dilutions of 7.6 x 10 4 and 2.5 x 10-6  respectively. 
2.24 Tail Cuff Plethysmography 
Systolic blood pressure was measured with an programmable 
sphygmomanometer, IITC Life Sciences, Diss, Norfolk, using tail cuff methods. 
Animals were lightly anaesthetised (1-2% Halothane in oxygen using an Acoma 
vaporizer F (International Market Supply, Congleton, UK)) in a perspex chamber 
before being transferred to a thermostatically controlled pad and maintained under 
anaesethesia during measurement using a mask. The heating pads maintained the rats 
at 33°C which were placed prone during measurements being taken. The duration of 
anaesthesia was kept to a minimum and equal for all animals tested. Systolic blood 
pressure (SBP) was defined as the initial arterial flow pressure detected. Diastolic 
blood pressure (DBP) was calculated from the SBP and MEP values using the equation 
DBP = (3 x MBP - SBP)/2. Five readings were taken for each measurement 
(Whitworth et al. 1994). 
2.25 Telemetric Blood Pressure Monitoring 
With most methods of continuous blood pressure anaesthesia, restraint or 
tethering are required. These requirements have all been shown to induce stress 
responses in rodents. Even with training of the animal tail cuff plethysmography is 
associated with a rise in systolic blood pressure. This means that this method is not 
suitable for continuous measuring of blood pressure. 
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Figure 2.4 
Diagram of the pressure transducer/transmitter implanted into the abdominal cavity of the 
rats monitored. 
Figure 2.5 
Diagramatic representation showing the position of the telemetric implant relative to the 
descending aorta. 
A radio-telemetry system allowed continuous intra-aortic recording of SBP, 
MBP, DBP,heart rate (HR) and motor activity with minimum stress placed on the 
animal. Direct blood pressure monitoring was performed using the Dataquest 
telemetric system from Data Sciences International, St. Paul, Minnesota, USA. 
Surgical implantation of a transmitter (TA1 1PA-C40) (see figure 2.4) containing a 
strain guage sensor resulted in arterial pressure conducted to the sensor via a 0.7 mm 	
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diameter catheter (see figure 2.5). 
The rat was maintained on 24% Halothane/air mixture, under constant 
supervision on a 37°C heat pad throughout the surgical procedure. All four limbs were 
taped to a cork base-plate to give access to the chest and abdominal region. The fur 
was shaved from the entire chest and abdominal region and the area wiped with 
ethanol. An incision was made using a scalpel (shape 10A) extending from below the 
sternum to the base of the abdomen. Fat and other organs were cleared from the 
descending aorta using cotton swabs. A region of the descending aorta was then teased 
from the attached tissue. A suture was threaded under the descending aorta and held 
tight to prevent blood flow. Whilst the blood flow was halted the aorta was pierced 
with a specially designed needle. The catheter was placed in the opening in the aorta 
and a small swab (2.5mm x 2.5mm) placed behind the vessel. A drop of Vetbond was 
used to seal the catheter in place and the suture remove slowly in case of any bleeding 
from the aorta. All swabs and instuments were removed and the transmitter was sewn 
into the abdominal wall. Finally the wound was closed using staples that fell out once 
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Figure 2.6 Diagramatic representation of the telemetric equipment used to monitor blood 
pressure continuously. 
The final 1cm of the catheter was coated with an anti-thrombic film and the tip 
filled with bio-compatible gel (see figure 2.4). The 5.5 - 6 week old male rats were 
placed in a cage which sat upon a receiver panel (RA 1010) which sent the signals to a 	
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consolidation matrix (BCM 100) which is decoded by a card in an Everex 386/25 
personal computer with accompanying software (Dataquest IV 2.2) (Bidani et al. 1993) 
and Microsoft OS/2 (see figure 2.6). 
A dual ambient pressure monitor (C11PR) measured barometric pressure to 
correct for the implant pressure relative to a vacuum. These signals were also sent to 













Figure 2.7 The Toshiba Capasee Diagnostic Ultrasound. The device could print copies 
of measurements taken or could send them directly to a personal computer. 
All measurements were made using a convex 7.5 MHz probe on a Toshiba 
Capasee Diagnostic Ultrasound System (see figure 2.7) with Clear Image ultrasound 
couplant from Diagnostic Sonar, Livingston. Animals were lightly anaesthetised with 
halothane (1-2%) and shaved in the left lateral position. After application of the 
couplant a two-dimensional B-mode image was used to guide an M-mode scan through 
the left ventricle (Jones et al. 1992). The image displayed is dependent on how the 
probe is applied. Various probe angles were attempted to obtain the image best suited 
for examination. The probe is provided with a mark (black arrowhead) that indicates 	
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the direction of the probe (see figure 2.8). End-diastole was identified as the widest 
diameter of the left ventricle during the cardiac cycle. Using on-screen digital calipers 
measurements (to 0.1mm) were taken of left ventricular end-diastolic diameter (EDD), 
diastolic interventricular septum (IVS) and diastolic peripheral wall thickness (PWT). 
Left ventricular mass (LVM) was then calculated using the cube formula: LVM = 1.04 
X [(EDD + IVS + PWT)3 - EDD3] (Sahn et al. 1978) where 1.04 is the specific 
gravity of myocardium. Five measurements of the form above were taken and the 
average of the five LVMs calculated. 
Figure 2.8 High freqency ultrasonic probe used with the Toshiba Capasee system. 
CHAPTER 3 
Construct Design and Production 
of Stable Transgenic Lines 
3.1 Construct Design 
In the rat, the renal juxtaglomerular (JG) apparatus is the only known site of 
prorenin conversion to active renin. To avoid any possibility of activation of prorenin-
2 by the JG apparatus, a fusion transgene was constructed which consisted of an 
expression cassette, based on the human a 1 anti-trypsin promoter, fused to the eDNA 
sequence encoding the mouse renin-2 protein. The design of the expression cassette 
(Jallat et al. 1990) enabled liver-specific expressionof a heterologous transgene. It 
was therefore expected that an alATfRen-2 fusion transgene would be expressed in, 
and secreted from, the liver without the possibility of expression in renal 
juxtaglomerular cells. The expected specificity of expression should simplify 
interpretation of any phenotype observed in the transgenic animals. 
One of the salient features of this vector was the provision of intronic sequences 
which are known to generally enhance the expression of transgenes (Wilson et al. 
1990; Choi et al. 1991). The use of the 5' portion of the first intron of the al 
antitrypsin gene not only provided this function, but was known to contain elements 
important for appropriate liver-specific expression (M. Courtney, personal 
communication). The 3' portion of the intron was replaced by a c-myc-derived splice 
acceptor sequence and cloning sites for permitting the generation of fusion constructs 
(Bernard et al. 1983). 
The pct lATJRen-2 fusion construct, illustrated in Fig. 3. 1, was initially prepared 
by amplifying the Ren-2d cDNA from plasmid pR2R2 by PCR (a gift from J. 
Mullins). The primers for the PCR contained the restriction sites Sail, which was 
found in the final construct at nucleotide 1970-1993 (all numbering is taken from the 
p(XlAT/Ren-2 where the EcoRl site is nucleotide 1), and HindIll (nucleotide 3224). A 
1886bp EcoRl/Sail restriction fragment from pTG3925, containing the human al anti-
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Schematic showing the structure of pc1ATIRen-2. Only restriction sites in key steps of 
construct generation are shown. Amp': ampicillin resistance gene. - : transcription 
start site for alATIRen-2, - direction of transcription of the amp' gene. 
complementary Sail sites into pSP72/Ren-2, see figure 3.1. The entire EcoRl/Hindlil 	
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restriction fragment of pSP72a1AT/Ren-2 was sub-cloned into Bluescript SKIT-. 
Finally, HindlIl and Xhol restriction sites were introduced to a SV40 poly A signal by 
PCR amplification of pRagUO.3ARXSV (GenBank Accession No., K02212 
nucleotides 3219-3232 and nucleotides 3430-3418). The modified SV40 poly A signal 
restriction fragment was then ligated through complementary HindIll/Xholsites in 
pSKa1AT/Ren-2 to give the final construct, palAT/Ren-2. The transgene was 
excised from p(X1AT/Ren-2 as an EcoRl/Xhol restriction fragment. 
3.2 Transfection of a1AT/Ren-2 Into HepG2 Cells 
The pc1AT/Ren-2 construct was transiently transfected into the human liver cell 
line HepG2 (Aden et al. 1979; Knowles et al. 1980) to validate its ability to be 
expressed and correctly spliced. RNA was prepared from the transfected cells and it 
was demonstrated by Northern blot hybridisation analysis that these cells produced a 
renin transcript of the predicted length (1.2kb), whereas sham-transfected cells did not 
produce a renin transcript (data not shown, Graham Barrett personal communication). 
Stable HepG2 derived cell lines expressing the palAT/Ren-2 construct were also 
produced in the laboratory. These cell lines were used to determine the proportion of 
prorenin to active renin secreted into the medium as determined by indirect 
radioimmunoassay for Al with and without trypsin activation (see Chapter 4, 4.5). 
The results showed that less than 1% of total renin was active and that there was 105 ± 
17 ng AJJml/h of prorenin present in the medium. Although a minor amount of 
activation cannot be excluded, the small amount of active renin detected in the medium 
is most likely due to proteolytic degradation of prorenin. Assuming that HepG2 cells 
are a representative model of rat liver cells, these results demonstrated, in principle, that 
the transgene would deliver high levels of prorenin directly into the plasma without 
activation in the liver. 
3.3 Micro-Injection and Screening of Offspring 
The ctlAT/Ren-2 transgene was introduced into both Sprague Dawley and 
Fischer/344 single cell embryos, in two independent series of micoinjections. Thirty-
two and one hundred and eighteen healthy offspring were obtained from the injection 
and reimplantation of one hundred and fifteen and five hundred and eighty-eight 
Sprague Dawley and Fischer embryos respectively. Similar success rates were 	
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Sprague Dawley 115 32 3 9.4% 
Fischer/F344 588 118 13 11.0% 
All viable offspring were screened for the presence of the a 1 AT/Ren-2 transgene 
by a transgene specific PCR analysis as described in Chapter 2, 2.7. Results from 
PCR screening of the offspring were confirmed by Southern blot hybridisation 
analysis. Sixteen tail DNAs gave the transgene-specific products during PCR analysis, 
and thirteen out of those sixteen proved positive by Southern blot hybridisation (see 
figure 3.2). Figure 3.2 shows the transgenic founders derived by microinjections as 
determined by Southern blot hybridisation. The plasmid palAT Ren-2 was diluted to 
the equivalent of ten copies per haploid genome in 10 j.tl of water. This was run as a 
transgene copy number control. The final percentage of offspring that were positive 
from the second microinjection series was 14.6%. Densitometric analysis 
demonstrated that there was a significant range of transgene copy number, from 
founder TG6 with approximately 5 copies per haploid genome, to founder TG8 with 
over 100. 
3.4 Nomenclature for Transgenic Animals 
A suggested nomenclature for transgenic animals is described in ILAR news 
(Institute of Laboratory Animal Research)(ILAR 1992). A transgene symbol, it 
suggests, should consist of three parts, all in Roman type, as follows: TGX 
(YYYY)####ZZZZ, where TGX indicates the mode of insertion of DNA (N for non-
homologous insertion, R for insertion via a retroviral vector, or H for homologous 
recombination). (YYYY) is the insert designation, indicating salient features of the 
transgene as determined by the laboratory. #### is the laboratory-assigned number, a 
unique number the laboratory assigns to each stably transmitted insertion after germ-
line transmission is confirmed. ZZZZ is the laboratory code, uniquely assigned to each 
laboratory that produces transgenic animals by ILAR (USA only). In our laboratory 
this nomenclature has been modified. TGX indicates whether the transgenic animals is 
mouse (M) or rat (R). (YYYY) is the insert designation and #### the animal number 
(see example below). There is no ZZZ code. In the case of a transgenic founder 
giving rise to more than one line of offspring, due to multiple integration sites (see 
TGR((x1AT/Ren-2)7647, figure 3.9), after the founder number there is a slash and the 
subtype number, eg. TGR((x 1 ATIRen-2)7647/2. 
eg. TGR(mRen-2)27 	or 
rat mouse Ren-2 founder 
animal ID 
TGR(al ATIRen-2)3375 
11-4 t 	t t 
rat a lAntitrypsin mouse animal ID 
Promoter 	Ren-2 
For the sake of brevity in my thesis, founder animals will be referred to as 
TG(founder number) and their offspring by founder number/animal number. Table 2.1 
below provides animal number, genetic background and founder animal. 
Table 3.2 
Animal Number Strain (Sprague Dawley or 
Fischer)  
Founder 
1694 SD TG2 
2529 SD TG2 
2532 SD TG2 
2533 SD TG2 
3373 - 3385 SD TG2 
1270 SD TG3 
8610 F TG7 
8611 F TG7 
8612 F TG7 
790 F TG7 
791 F TG7 
626 F TG12 
627 F TG12 
3188 F TG12 
3189 F TG12 
3.5 Creation of Transgenic Lines 
In order to study both expression of the cxlAT/Ren-2 transgene and any 
phenotype the transgenic animals may have had it was necessary to breed extensively 
both from founder animals and males from the G 1  generation. Transgenic males were 
used as they could be paired with more than one non-transgenic female at a time, thus 
producing more offspring. 
One transgenic founder, TG 1, died at five weeks of age, exhibiting extreme left 
ventricular cardiac hypertrophy. This suggested that the animal may have suffered 
from high blood pressure and therefore, as a precaution, the subsequent founders were 
maintained on Captopril at 10mg/kg per day to control their blood pressure. 
Angiotensin-converting enzyme (ACE) inhibitors, such as Captopril and Enalapril, 
block the conversion of angiotensin I to angiotensin II, promote vasodilation and 
decrease aldosterone levels. ACE inhibitors also block the degradation of bradykinin, a 
vasodilator, which results in increased levels of plasma bradykinin. 
For each of the two founders, TG2 and TG3, three litters were produced and a 
male transgenic positive animal from each line (animals TG2/1694 and TG3/1270 
respectively) was set aside for future breeding, see table 3.2. There were four litters in 
the G2 generation of TG2 from which two males, TG2/2529 and TG2/3374, and one 
female, TG2/3377, were treated with Captopril and maintained as breeders (see figure 
3.3 for an example of an TG2 Southern blot hybridisation analysis, 3.3E for an 
example of the results obtained from the transgene-specific PCR and figure 3.4 for a 
partial pedigree). 
All offspring from TG2/2529 were sacrificed for tissue analysis or telemetry 
leaving offspring from TG2/3374 and TG2/3377 for future breeding. Scanned images 
and densitometric analysis showed transgenic positive animals from previous litters had 
a transgene copy number of approximately 30. The offspring of animals from 
TG2/3373-3386, however, showed a copy number of one consistent with non-
transgenic animals, see figure 3.6. All animals from the other breeding litters had been 
used in expression analysis studies, resulting in the apparent loss of the transgene 
array in line TG2. There may have been a rearrangement that left fragments of 
transgene to produce a positive PCR signal or perhaps there was a complete deletion of 
the transgene locus and contamination of the tail DNAs. With second tail biopsies 
producing DNA which gave the same transgenic positive PCR products it is unlikely, 
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Panel A: PCR screening of potential founder animals, TG4 - TG16. Those PCRs 
that showed products of 580bp and 125bp were tested by Southern blot 
hybridisation analysis. The x marks denote possible PCR positive signals that 
were proved to be negative by Southern blot hybridisation. Panel B: Transgenic 
founders derived by microinjection as determined by Southern blot hybridisation. 
Genomic DNA (10tg) was digested with 2.5U of PstI and Southern blotted as 
described in Chapter 2, 2.12. The probe used was the Sall/Hindill fragment of 
Ren-2 cDNA, see Chapter 2, 2.11. The plasmid pcU AT/Ren-2 was diluted to the 
equivalent of ten copies per haploid genome in 10 t1 and run as an indication of 
the range of transgene copy number present in the Fischer founder animals 
(TgxlO). The size markers used were ?HE, see Chapter 2, 2.8 and non-
transgenic rat DNA was used as a negative control. 
The line TG3 was bred to characterise the line (see figure 3.3B for an example of 	
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a TG3 Southern blot). Line TG3 did show an elevated blood pressure but this was not 
as severe as in line TG2. There was never a malignant phase to the blood pressure and 
the mortality rate of line TG3 was very low. Animals from the line TG3 did not show 
any abnormalities in their plasma RAS or exhibit any clinical signs of hypertension. 
This line was, therefore, not extensively bred or studied in detail. 
Two litters from each of the founders TG4 - TG 16 were required to produce 
enough transgenic positive animals for the initial physiological analysis of these lines 
(see figure 3.5 for pedigree). Four founders (TG5, TG8, TG9 and TG 15) did not pass 
on the transgene to their progeny, see table 3.2, and founder TG 10 did not produce any 
progeny. Founder TG1 1 produced offspring that showed two separate Southern blot 
hybridisation patterns with a Pst I restriction digest of tail DNA (see figure 3.7). The 
two Southern blot hybridisation patterns were treated as individual lines and bred 
separately. Founder TG 16 only produced one litter and both transgenic pups died soon 
after birth. After the blood pressure data was collected from the offspring of the 
remaining founders it was decided to maintain the 6 lines that produced two litters and 
to breed extensively from founders TG7 and TG12 as they had demonstrated the 
highest blood pressures as measured by tail cuff plethysmography. Southern blot 
analysis was used to determine that the integrity of the transgene array was maintained 
between generations of both transgenic lines, TG7 and TG12, see figure 3.9. Figure 
3.9 shows Southern blot hybridisation of three generations of transgenic lines TG7 and 
TG12. 
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Figure 3.3 
A: Southern blot hybridisation of 1Otg of genomic DNA from progeny of TG2 
digested with 2.5U of Pvu II. The probe used was the Sall/HindIll fragment of Ren-2 
cDNA, see Chapter 2, 2.11. Lane 1, known non-transgenic; Lanes 2, & 4 non-
transgenics ; Lanes 3 & 5 transgenic. B: Southern blot hybridisation of 10tg of 
genomic DNA from progeny of TG3 digested with 2.5U of Pst I. Lane 1 & 2 known 
non-transgenic3; Lanes 2-6 transgenics. C: Genomic DNA from progeny of TG2 
digested with 2.5U of Pvu II, visualised by ethidium bromide/U.V. light, prior to 
Southern blot hybridisation shown in panel A, markers used was 2H3/R1 (See 
Chapter 2, 2.87) D: Genomic DNA from progeny of TG3 digested with 2.5U of Pst 
I, visualised prior to Southern blot hybridisation shown in panel B, markers used were 
X/HindIII. E: PCR gel showing the results obtained from no DNA (Lane 1), 
transgenic positive DNA (Lane 2) and transgenic negative DNA (Lane 3) - See 
Chapter 2, 2.7 for details of PCR reaction. 
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Partial pedigrees of the main transgenic lines. Only animals quoted in th etext 
are shown here. Square symbols denote male animals and circular symbols 
denote female animals. Symbols that are half-shaded denote a hemizygous 
transgenic animal. Lines indicate where the pedigrees extend. Numbers 
below symbols are unique identifying numbers used in the laboratory. 
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Figure 3.5 
Initial pedigrees of transgenic lines TG2 - TG 16. See table 3.2 for a 
summary of all founder animal breeding. TG 11 sublines are shown under 
the litter numbers. Square symbols denote male animals and circular 
symbols denote female animals. Symbols that are half-shaded denote a 
hemizygous transgenic animal. Numbers are unique identifying numbers 







Founder Phenotype Outcome 
TG 1: 3 - Severe left ventricular 
hypertrophy 
Founder died at 5 weeks of 
age 
TG2: 5 6 Chronic and malignant 
hypertension  
Line established 
TG3: 2 5 No discernable phenotype Line established 
TG4: 14 2 High blood pressure Initial study only 
TG5: 2 2 - Did not pass on transgene 
TG6: 2 2 High blood pressure Initial study only 
TG7: 8 6 Chronic and malignant 
hypertension  
Line established 
TG8: 50 1 - Only 1 litter born and pups 
died 
TG9: 25 2 - Did not pass on transgene 
TG10: 6 - - Did not breed 
TG 11: 3 2 High blood pressure Initial study only 
TG12: 5 6 Chronic and malignant 
hypertension  
Line established 
TG 13: 2 2 High blood pressure Initial study only 
35 2 High blood pressure Initial study only 
40 1 - Did not pass on transgene 
TG 1: 26 1 - Transgenic pups died 
Wei 




Southern blot hybridisation analysis of genomic DNA (lOj.ig), digested with 
2.5U of BamHI, from animals from transgenic line TG2. Lanes 1-5 show 
samples that gave PCR results consistent with a transgenic animal, lane 6 is a 
sample of non-transgenic DNA. The probe used was the Sall/HindIll 
fragment of Ren-2 cDNA (see Chapter2, 2.8). Size markers are indicated on 
the left of the figure. 
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Southern blot hybridisation analysis of the sub-line divisions of transgenic 
line TG 11. Genomic DNA (1 Ogg) from the G2 generation of TG11 was 
digested with 2.5U of BamHI. The probe used was the Sall/Hindlil 
fragment of Ren-2 cDNA. Two hybridisation patterns were noted in the 
transgenic samples and designated type 1 and type 2 (See Chapter 2, 2.4 for 
nomenclature). 
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Figure 3.9 
Southern blot hybridisation of three generations of transgenic lines TG7 and TG12. 
Genomic DNA (lOj.tg) was excised with 2.5U of PstI and Southern blotted as 
described in Chapter 2, 2.11. The probe used was the Sall/Hindill fragment of the 
Ren-2 cDNA as described in Chapter 2, 2.8. The negative sample was DNA from 
a non-transgenic animal. Markers used were 4HE as described in Chapter 2, 2.8. 
The linkage relationship between the animals used for the Southern blot are 
indicated above. 
CHAPTER 4 
Expression Analysis of Transgenic 
Offspring 
4.1 Isolation of RNAs 
Samples were taken from a range of tissues and processed as described in 
Chapter 2. The integrity of all RNAs was demonstrated by gel electrophoresis. 
Tissues taken for Northern blot analysis include, liver, kidney, adrenal gland, SMG, 
heart, lung, testes, thymus, whole brain, spleen and muscle. Figure 4.113 shows a 
representative gel with total RNAs extracted from a variety of tissues. Total RNA was 
used in Northern blot hybridisation analysis and RNase protection analysis. However, 
poly A+ mRNA was purified from total RNA and used in certain Northern blots, in an 
attempt to increase the sensitivity of the assay. 
4.2 Northern Blot Analysis 
In TG2 and TG3 transgenic rats the Northern blot analyses showed no detectable 
transgene transcript, see figure 4. 1A. Total and mRNA Northern blot analyses were 
carried out on five male and female samples when the TG7 and TG12 transgenic rats 
were tested for expression. Again, no detectable transcript was seen with total RNA in 
any of the tissues tested, as shown in figure 4.2A. The Northern blots carried out on 
the same samples using mRNA, however, did reveal a renin-specific transcript in the 
liver samples of trangenic, but not wild type animals. In figure 4.213 renin RNA 
transcripts were detected in the liver and kidney samples. The absence of any renin-
specific hybridisation signal, in the rat kidney samples, when subjected to total RNA 
Northern blot hybridisation may be due to the poor cross hybridisation of the mouse 
Ren-2 cDNA probe to rat renin RNA. This was not seen when the renin message was 




Total RNA Samples 
Figure 4.1 
Panel A: Northern blot hybridisation analysis of total RNA (50ig) from a 
male from transgenic line TG2. Mouse (DBA/2J) SMG RNA (2Ig total 
RNA) was used as a positive control. The probe used was the Sail/Hindu! 
fragment of Ren-2 cDNA, see Chapter 2.11. Panel B: Ethidium bromide 
stained agarose gel demonstrating the integrity of the RNA samples in panel 
A. 
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Figure 4.2 
Panel A: Northern blot hybridisation analysis of total RNA (5Opg) from transgenic 
line TG7 and TG12. Mouse (DBAI2J) SMG RNA (2tg total RNA) was used as a 
positive control. The probe used was the Sall/HindIll fragment of Ren-2 cDNA, see 
Chapter 2, 2.11. Panel B: Northern blot hybridisation analysis of poly (A)+ RNA. 
Samples were taken from a transgenic male from line TG7, poly (A)+ RNA was 
prepared as per chapter 2.13. RNA was loaded (5tg of sample poly(A)+ RNA) and 
the procedure was that followed for a total RNA Northern blot (chapter 2.15). The 
top panel in 4.2B shows the Northern blot hybridised with the Sall/Hindlil fragment 
of Ren-2 cDNA, see Chapter 2, 2.11. The bottom panel in 4.2B shows the same 
Northern blot hybridised with an EcoRI/BainHi fragment of GAPDH cDNA. 
Due to the availability and sensitivity of RNase protection analysis it was felt that 
it was suitable to ascertain whether small, but perhaps significant, expression of the 
transgene could be detected in any of the previously tested samples. 
4.3 RNase Protection Analysis 
The RNase protection assay used produces a specific protected fragment of 250 
nucleotides. This assay is specific for Ren-2 transcripts and does not detect Ren-] or 
rat renin transcripts (Field et al. 1984). In rat lines TG2 and TG3 it was shown that 
they produce the Ren-2 transcript in the liver at relatively low levels. Previous al anti-
trypsin derived transgenes have shown some expression in the testes, lung, and adrenal 
(Dalemans et al. 1990). The construct used here, however, only demonstrated 
expression in the liver as was reported by Sifers et al 1987 (Sifers et al. 1987). The 
RNase protection assays on the TG2 and TG3 transgenic rat lines confirmed the 
absence of Ren-2 RNA transcript in any organ, other than the liver, as suggested by 
Northern blot hybridisation analysis. Due to the absence of any ectopic expression, 
physiological effects could be ascribed to the production of mouse Ren-2 protein from 
a single organ of origin. It was anticipated that the hepatic cells were not capable of 
storing renin as human HepG2 derived cells could express the transgene, in a transient 
transfection, and that the protein was constituitively secreted into the media, see 
Chapter 3, 3.2. 
The relative levels of Ren-2 specific transcript, as detected by RNase protection 
analysis, in lines TG2 and TG3 was greater in line TG2 as shown in figure 4.3. This 
was thought to play a role in the subsequent differences in the phenotype seen between 
lines TG2 and TG3. Expression levels of transgenic transcript vary greatly depending 
on the site of integration and the construct used. Due to factors such as variations in 
mRNA stability, however, transcript levels do not always correlate with the observed 
protein levels. Expression levels did vary between lines, as did the observed blood 
pressure, and to a certain extent between the sexes. There appeared to be a higher 
level of a Ren-2 specific transcript, and higher level of systolic blood pressure, seen in 
both TG2 and TG3 male samples than in their female counterparts. As there was no 
internal loading control, this may be not be significant. 
The RNase protection assays performed on five male and female samples from 
TG7 and TG12 demonstrated similar results to those seen with the TG2 as shown in 
figure 4.5. Expression of the Ren-2 transcript was only detected in the liver and no 
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Figure4.3 
RNase protection analysis of samples from male and female transgenic animals from 
lines TG2 & TG3. Total RNA (20jig) was hybridised with a Ren-2 specific probe, 
see Chapter 2, 2.16. The samples were electrophoresed on a 6% polyacrylamide 
gel before drying the gel and placing it in an autoradiography cassette with Fuji 
autoradiography film. The film was exposed overnight at -70°C. 
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RNase protection analysis of samples from male transgenic animals from lines TG7 
& TG12. Total RNA (20 jig) was hybridised with a Ren-2 specific probe, see chapter 
2, 2.16. The samples were electrophoresed on a 6% polyacrylamide gel before 
drying the gel and placing it in an autoradiography cassette with Fuji 
autoradiography film. The film was exposed overnight at -70°C. 
other organ tested. There appeared to be a higher level of Ren-2 specific transcript, and 
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higher level of systolic blood pressure, seen in both TG2 and TG3 male samples. As 
there was no internal loading control, this may be not be significant. 
4.4 Immunohistochemistry in Sprague Dawley and 
Fischer Transgenic Rats 
A polyclonal rabbit renin antibody raised against Ren-2 protein was kindly 
donated to the laboratory by Professor John Baxter. The antibody bound to all mouse 
prorenins, renins and cross-reacted with rat renin. It was used to detect the presence of 
prorenin or renin protein in small, localised areas. In general, little staining was seen in 
the transgenic line TG3. In wild type animals the brown diaminobenzidine (DAB) 
chromophore produced by the reaction of the Horse Radish Peroxidase antibody (see 
figure 4.5) was seen localised to the area of the juxtaglomerular apparatus of a few 
glomeruli as was expected of a normotensive sample see figure 4.6. Staining in the 
liver samples of all transgenic lines (22 samples taken) showed low-level diffuse 
staining in the small arteries as would be consistent with secretion of the protein into 
the blood stream. The staining in the kidney sections was qualitatively seen as 
comparable between the transgenic and non-transgenic samples. Intense staining of 
renal tubules was seen in a few cases, however, where animals were in the final stages 
of malignant hypertension. In these cases intense DAB staining was seen, not only in 
the JG cells, but at specific points of the renal tubules (see figure 4.7). It may be that 
due to the high blood pressure, interlobular arteries had become hypertrophic and 
occluded resulting in local hypotension causing a release of renin from the JG cells and 
through the renal tubules (see chapter 6 for a complete explanation). At high 
magnification there was seen a striated pattern of staining in the renal tubule. The 
functional significance of this remains unclear but no such staining pattern was 
recorded in non-malignant or control animals. 
The only other area that was shown to contain renin protein was the small arteries 
of the heart in transgenic positive animals from lines TG8 and TG12 as shown in figure 
4.8. It is often thought that a physiological consequence of the high blood pressure 
seen in these animals was cardiac hypertrophy (Messerli et al. 1992). In a few animals 
staining with the renin antibody was seen in the cells of the small arteries of the heart. 
This observation was not wide spread, not every transgenic animal demonstrated this 
staining and not every small artery was stained in those that did. Unlike the staining 





Figure 4.6 Immunohistochemical analysis of renal sections from 6 week old (A) 
non-transgenic and (B) transgenic TGR((xlATIRen-2) rats using a total renin antibody. 
G: Glomerular Tuft, A: Afferent Arteriole. Panel (A) is a counterstained paraffin 
section (3im thick) (x400); whereas panel (B) has no counterstaining (x400). Both 
panels shown DAB staining of the juxtaglomerular apparatus. 
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Figure 4.7 Immunohistochemical analysis of renal sections (3im thick) from a 7 week 
old transgenic rat which suffered from malignant hypertension. The intense staining 
was seen in the renal tubules. Panel (A) (xlOO), panel (B) (x400). 
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Figure 4.5 
Diagrammatic representation of the Horse Radish Peroxidase (HRP)IDAB reaction. 
Diaminobenzidine is an exceptionally sensitive substrate for HRP that can be further 
enhanced by the addition of cobalt or nickel ions to the substrate solution. The drawback 
to DAB is that it reacts so quickly that it is easily overdeveloped giving high background 
(Harlow et al. 1988). 
within the cells of the small arteries. Rather, there was a more diffuse staining in the 
epithelial cells of the small arteries. As the end product of the RAS is, however, 
implicated in hypertrophy of the heart, and renin is the only component of that pathway 
not conclusively demonstrated to be produced by the heart, it is possible that there is 
some form of uptake which plays a part in the hypertrophy seen here (von-Lutterotti et 
al. 1994). 
4.5 Plasma Renin-Angiotensin System 
Plasma samples were collected as EDTA plasma, obtained from the retroorbital 
plexus after light anaesthesia. The plasma active and inactive (prorenin) renin 
concentrations were determined according to the method of Glorioso et al 1983 
(Glorioso et al. 1983). To activate prorenin 20i1 of plasma was incubated with 40p1 of 
trypsin (400 U/mi dissolved in TES buffer: 0.1M TES, pH 7.2 0.01% neomycin, 10 
mM EDTA). Samples were incubated on ice for 10 minutes and the reaction stopped 
by addition of 40p1 of soybean trypsin inhibitor (600 U/mi in TES buffer). To 
measure active renin 80j.ti of TES-buffer was added to the sample without trypsin. The 
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Figure 4.8 Immunohistochemical analysis of cardiac sections (3im thick) from 6 
week old (A) non-transgenic and (B) transgenic TGR((x1AT/Ren-2) rats. Both 
sections show small cardiac arteries treated with a total renin antibody. Both panels are 
counterstained with eosin. Panel (A) (xlOO), panel (B) (x 100). 
nephrectomized rat plasma (80mg/mi, 0.11% 2,3 dimercapto- 1 -propanol, 1.15mg/mi 	
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8-hydroxychinolin in TES buffer). The reaction was stopped with RIA buffer (0.1M 
Tris-acetate, pH7.4). Generated ANG I was measured by a radioimmunoassay 
(Hermann et al. 1988). Samples were divided into male and female, transgenic and 
non-transgenic. The comparison between male transgenic and non-transgenic rats from 
lines TG2 and TG3 showed that line TG2 had an extremely high level of circulating 
prorenin whereas line TG3 had a smaller, but significant, increase in plasma prorenin 
level. This may reflect the differences seen in transgene transcript level as detected by 
RNase protection. The only other statistically significant result was seen between the 
circulating All levels of line TG2 males and non-transgenic litter mates (p<0.05, 
unpaired student t-test). The All level seen in line TG2 males was marginally elevated 
when compared to controls. The results from the female transgenic and non-transgenic 
animals in both lines TG2 and TG3 were similar to those of the males. However, the 
level of prorenin detected was slightly lower in the female transgenic rats from line 
TG2 when compared to male transgenics from the same line. There was also no 
significant difference in the levels of circulating All seen between female transgenic and 
non-transgenic animals from line TG2. 
A similar sampling method was used for Fischer transgenic animals. Males from 
line TG7 showed significantly elevated prorenin levels. There were also no significant 
differences in levels of renin, Al or All when compared with male non-transgenic litter 
mates. Line TG12 transgenic males also showed a characteristic elevation in plasma 
prorenin with no associated rise in plasma renin, Al or All. Despite blood pressure 
and pathology data corresponding between TG2, TG3 and TG7, TG12 transgenic 
males, the Fischer males at 31 days of age demonstrated a much smaller rise in plasma 
prorenin of approximately 360ng AI/ml/h compared with approximately 17000ng 
AJJmIlh seen in the transgenic line TG2 males. 
As well as initially choosing a single time point of 31 days to study the plasma 
renin-angiotensin system in the transgenic animals a time course was also undertaken. 
Both transgenic lines TG7 and TG12 showed plasma prorenin levels of approximately 
bOng ANGI/ml/h as compared to 7ng ANGIJm1/h in non-transgenic controls at 4 
weeks of age. The non-transgenic animals showed a very small increase in plasma 
prorenin levels by six weeks of age. In contrast, both sets of transgenic animals had 
elevated plasma prorenin levels of approximately 4000ng ANGI/mIJh at five weeks of 
age and 3500ng ANGlJmIIh at six weeks of age, which were not significantly different 
to the week five results. The plasma active renin levels for all three groups are shown 
in table 4.1. There were no significant differences in the results obtained for the 
transgenic and non-transgenic animals. 
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fl Tg(-) 


















Panel A: Plasma prorenin levels in TG2 and TG3 transgenic and non-transgenic 
animals. Prorenin levels were measured by indirect RIA (see chapter 4, 4.5 for 
method) Five animals were tested in each group, variation is given as one 
standard deviation of the mean. Panel B: Plasma prorenin levels in TG7 and 
TG12 transgenic and non-transgenic animals. Five animals were tested in each 
group, variation is given as one standard deviation of the mean. All animals 
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Panel A: Plasma renin levels in TG2 and TG3 transgenic and non-transgenic 
animals. Renin levels were measured by indirect RIA (see chapter 4, 4.5 for 
method) Five animals were tested in each group, variation is given as one 
standard deviation of the mean. Panel B: Plasma renin levels in TG7 and TG12 
transgenic and non-transgenic animals. Five animals were tested in each group, 
variation is given as one standard deviation of the mean. All animals were five 













1132 Male '1133 Male 1132 Female 1133 Female 
TG2 Male TG3 Male TG2 Female TG3 Female 
Figure 4.11 
Panel A: Plasma angiotensin I levels in TG2 and TG3 transgenic and 
non-transgenic animals. Angiotensin I levels were measured by direct RIA (see 
chapter 4, 4.5 for method) Five animals were tested in each group, variation is 
given as one standard deviation of the mean. Panel B: Plasma angiotensin II 
levels in TG2 and TG3 transgenic and non-transgenic animals. Five animals 
were tested in each group, variation is given as one standard deviation of the 
















1137 Male 31312 Male 1137 Female RH 2 Female 
TG7 Male TG 12 Male TG7Female TG 12 Female 
Figure 4.12 
Panel A: Plasma angiotensin I levels in TG7 and TG12 transgenic and 
non-transgenic animals. Angiotensin levels were measured by direct RIA (see 
chapter 4, 4.5 for method) Five animals were tested in each group, variation is 
given as one standard deviation of the mean. Panel B: Plasma angiotensin TI 
levels in TG7 and TG12 transgenic and non-transgenic animals. Five animals 
were tested in each group, variation is given as one standard deviation of the 
mean. All animals were five weeks of age. 
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Table 4.1 
Renin (ngANGI/mI/h) Ang I (fmoVml Ang II) 
Week  5 6 4 5 6 
TG7 14 ± 2.7 18 ± 3.3 18 ± 4.2 1.2 ± 0.52 1.7 ± 0.42 1.6 ± 0.51 
TG12 11±3.9 13± 2.5 16±3.7 1.1 ± 0.78 1.5±0.60 1.8±0.43 
(-yes) 1 	8 ± 2.4 10 ± 2.1 11 ± 3.0 1 0.8 ± 0.15 0.9 ± 0.29 0.9 ± 0.36 
Figure 4.13 
Plasma prorenin levels in TG7 and TG12transgenic males over a three week 
period. Levels were measured by indirect RIA (see chapter 4, 4.5 for method). 
Five animals were tested in each group, variation is given as one standard deviation 
of the mean. Plasma renin and All levels are given in table 4.1. 
The transgenic female animals from lines TG7 and TG12 also showed prorenin 
levels that were elevated with respect to non-transgenic controls (280ng AJlml/h and 
lOng AIJIT1I/h respectively). All renin, Al and AT! measurements showed no significant 
differences when compared to non-transgenic litter mates. By RNase protection there 
appears little difference between transcript levels but the RIA demonstrated a significant 
difference between protein levels. It was reported that in mice carrying a transgene 
consisting of this promoter and human Factor IX there was considerable variation in 
the levels of protein produced by different transgenic lines and as not all TG4 - TG16 
lines produced were sampled it may be that other Fischer lines had plasma prorenin 
levels comparable to that seen in the lines TG2 or TG3. 
4.6 Mouse and Rat Plasma Renins 
To determine the contribution of mouse renin to the plasma renin content, the 
samples were incubated for 2h at 4°C with a monoclonal antirenin antibody, specific for 
murine renin with <3% cross-reactivity to purified rat renin (provided Dr. Jorg Peters 
from a donation by Dr. Celio, Universté Pérolles, Switzerland). Antibody/renin 
complexes were precipitated with formalin fixed Staphylococcus aureus protein A. The 
renin activities were determined before the procedure and in the supernatant after 
immunoprecipitation. 
Transgenic male animals from line TG2 showed 75% of plasma active renin was 
derived from the a 1 anti-trypsin/Ren-2 transgene. Despite demonstrating a lower 
plasma prorenin level, transgenic male animals from line TG3 also showed that 70% of 
plasma active renin was transgene derived. These results were reflected in the 
transgenic females from lines TG2 and TG3 where they showed 68% and 71%, 
respectively, of plasma active renin was transgene derived. 
Despite a difference in genetic background from the Sprague Dawley animals the 
transgenic males from lines TG7 and TG12 also showed transgene-derived plasma 
active renin levels of approximately 83% (80% and 87% respectively). Consistent with 
these results, transgenic Fischer females from lines TG7 and TG12 showed levels of 
plasma active renin of 76% and 79% respectively. There is no clear reason for such 
similar results unless there is some form of feedback mechanism involved that can 
regulate mouse renin in rat plasma. Also, as there is an increased level of plasma 
• Male TG2 (+) 
O Female TG2 (+) 
• Male TG7 (+) 
W Female TG7 (+) 











Percentage contribution of transgene derived active renin in the plasma as 
determined by immunoprecipitation and RIA. There were five animals in each 
group and variation is given as one standard deviation from the mean. All 
animals were five weeks of age. 
prorenin in the transgenic animals it suggests that the difference between wild type and 
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transgenic animals is due to transgene expression. Yet, despite extensively elevated 
levels of plasma prorenin in lines, TG7 and TG 12 the percentage of plasma active renin 
in these lines is similar to that of line TG3 which demonstrated a much more modest 
increase in plasma prorenin. Therefore the percentage of plasma active renin which is 




Physiological Data From 
Transgenic Lines 
5.1 Growth Curves 
Due to an obvious difference in apparent growth rate in the transgenic animals, 
weight measurements were taken weekly on groups of transgenic and non-transgenic 
animals. Transgenic males from line TG2 showed a significant difference in weight as 
early as three weeks of age when compared to non-transgenic controls, see figure 
5. 1A. These animals gained weight at a slower rate than the non-transgenic controls 
and continued to be significantly smaller than their non-transgenic counterparts. Males 
from transgenic line TG3 did not show a significant difference in weight at three to 
seven weeks of age when compared to control animals, see figure 5. 1A. Studies were 
only carried out up to seven weeks of age due to the high mortality rate seen in the 
untreated transgenic animals (see following section). The lack of normal weight gain 
did not appear to be due to obstruction of the digestive tract or behavioural differences. 
The trend of low weight gain was also seen in the male Fischer transgenic 
animals. At four weeks of age males from line TG7 weighed, on average, 74g ± 5.7g 
as compared to 86g ± 6.3g seen in the non-transgenic animals, see figure 5.2A. 
Fischer transgenic males from line TG12 also showed a lower weight at four weeks of 
age (85 ± 4.9g) but it was not significantly different to non-transgenic animals, see 
table 5.1. By five weeks of age there were significantly lower average weights of both 
Fischer transgenic lines (TG7; 87 ± 9.6g, TG12; 112 ± 3.3g) when compared to the 
weight of the non-transgenic animals (148g ± 10.6g). 
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Figure 5.1 
Panel A: Weight gain in the transgenic TG2 and TG3 groups. Panel B: Mortality 
rate in the transgenic TG2 and TG3 groups. Ten male animals were monitored in 
each group initially. Ten animals were tested in each group, variation is given as 
one standard deviation of the mean. 
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Figure 5.2 
Panel A: Weight gain in the transgenic TG7 and T012 groups, variation is given 
as one standard error of the mean. Panel B: Mortality rates in theTG7 and TG 12 
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Figure 5.3 
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A: Output from the IITC Life Sciences Programmable Sphygmomanometer. Non-
transgenic TG2 male 6 weeks of age trace. B: Transgenic TG2 male 6 weeks of age, trace. 
C: Tail cuff blood pressure measurements (systolic blood pressures) over a four week 
period. Ten male animals were monitored in each group and variation given as one 
standard error of the mean. 
5.2 Mortality 
As previously mentioned, transgenic rat lines TG2, TG7 and TG12 exhibited a 
high mortality rate in the first two months of life. Sprague Dawley founder transgenic 
male TG1 died at five weeks of age, before reaching sexual maturity. Animals from 
line TG2 demonstrated a very steep mortality curve with less than 50% survival of 
untreated males by six weeks of age, see table 5.2 and figure 5. lB. The cause of death 
in the transgenic animals was renal failure, cardiac hypertrophy or stroke, all associated 
with chronic or acute high blood pressure. Conversely, line TG3 demonstrated an 
almost normal mortality rate in the first seven weeks of life. As no severe pathology 
was ever seen in samples from line TG3 it was concluded that it was an altered 
phenotype from that seen in line TG2, perhaps due to the normal circulating prorenin 
levels seen. 
Both Fischer lines showed mortality rates similar to that seen in line TG2. In the 
study of Fischer line TG7 one male died before four weeks of age and by seven weeks 
of age only two untreated males survived. The mortality rate for line TG12 
demonstrated a higher rate with no surviving males at the end of the study, see figure 
5.213. No control animals died in the first seven weeks of life. It was noted that the 
three founder male animals from line TG2 and one each from lines TG7 and TG12 
treated continuously with Captopril from weaning survived the seven week study. 
5.3 Tail Cuff Plethysmography 
Tail cuff plethysmography was carried out on both TG2 and TG3 lines at regular 
intervals. Only mean blood pressure and systolic blood pressure measurements were 
taken, as diastolic blood pressure was not measured, by the IITC sphygmomanometer, 
rather it was calculated using the formula; 
Mean Diastolic Pressure = (3 x MBP) - SBP)/2. 
Due to the requirement for anaesthesia in the protocol, four weeks was routinely 
used as the minimum age at which the animals were anaesthetised and the animals 
required a minimum of five days to recover. Both transgenic males and females from 
line TG2 demonstrated systolic blood pressures significantly higher than the non-
transgenic control group. The TG2 males demonstrated a steep rise in systolic blood 
pressure from four to seven weeks of age (129 ± 3mmHg - 184 ± 16 mm}Ig). This 
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rise was mirrored by the blood pressure measurements from the TG2 females (120 ± 6 
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mmHg - 185 ± 22mmHg). Blood pressure measurements from line TG2 females were 
lower, but not significantly so, when compared to transgenic males from the same line. 
The Sprague Dawley transgenic animals from line TG3 showed no significant 
difference in blood pressures, at any age, when compared with the non-transgenic 
controls. It has been postulated that the normal blood pressures seen in transgenic 
males and females from line TGR TG3 are due to the normal levels of prorenin and 
other constituents of the renin-angiotensin system seen in these animals. Also it has 
been reported that in humans small variations in blood pressure, at an early age, may 
indicate larger variations to the norm in adult life. Systolic blood pressures for both 
males and females from line TG2 were elevated, but not significantly so, at four weeks 
of age. The large increase in blood pressure seen in the following weeks is consistent 
with the findings in humans. As blood pressure measurements required anaesthesia, as 
previously mentioned, readings were only taken once a week. This meant that any 
rhythm, diurnal or otherwise, could not be detected using this method. The maximal 
blood pressure reached by the male TG2 animals (-200nMnHg systolic) was similar to 
that reached by the transgenic line TGR(mRen-2)27. Despite lower plasma prorenin 
levels in the TGR(mRen-2)27 the maximal blood pressure was similar to that seen in 
line TG2 but TGR(mRen-2)27 demonstrated a more gradual increase in blood 
pressure. The TGR(mRen-2)27 rats reached a plateau at 200mmHg at 10-12 weeks of 
age whereas line TG2 animals had reached systolic blood pressure of 200mmHg by 
seven weeks of age. The difference in blood pressure increases between TGR(mRen-
2)27 and the line TG2 animals could be due to their respective plasma prorenin levels. 
Of the thirteen Fischer founder animals seven produced offspring that carried the 
transgene. Two litters were bred from each founder, and blood pressure measurements 
were taken by tail cuff at six weeks of age (Table 5.3). The range of systolic blood 
pressures exhibited by the G2 offspring was between 141 ± 4.6 mmHg (lines TG 11 
and TG15) and 182 ± 6.3 mmHg (line TG7). Non-transgenic control animals 
exhibited systolic blood pressure of 113 ± 2 mmHg. 
Both Fischer transgenic lines TG7 and TG12 showed increases in systolic blood 
pressure, which were statistically significant at four weeks of age, unlike the TG2 line. 
Transgenic line TG7 males showed systolic blood pressure of 129 ± 8mmHg whereas 
males from line TG12 showed blood pressures of 127 ± 15 mmHg compared with 
non-transgenic males which demonstrated blood pressure of 96 ± 9 mmHg at four 
weeks of age. Both transgenic lines showed steep increase in blood pressure in the 
region of 40 mmHg in weeks four to six whereas the non-transgenic control animals 
demonstrated an increase of 15 mmHg over the same time period. The standard 
Table 5.1 
Founder TG4 TG6 TG7 TG1 1 TG12 TG13 TG14 Non Tg 
Nos. 4 2 7 6 6 7 6 20 
Transgenic 
(+ve)  
Mean SBP 148 166 182 141 177 155 141 113 
(mmHg) ±5.6 ±8.1 ±6.3 ±4.7 ±4.3 ±5.2 1 	±3.9 ±2.2 
Tail cuff plethysmography data from transgenic Fischer lines 
deviation values for the transgenic groups are high due to sharp increases in blood 
pressure of individual animals at different time points and the high mortality rate which 
meant that at the end of the study period only four males remained in each of the 
transgenic groups. 
The transgenic females from both TG7 and TG12 lines followed similar profiles for 
systolic blood pressure over the four week trial. As was the case for the female 
animals from line TG2, the female transgenic animals showed a lower systolic blood 
pressure at four weeks of age, when compared with transgenic males from line TG7 
and TG12, however it was not statistically significant. By week seven both transgenic 
female groups had demonstrated blood pressures of approximately 190 mmHg and 
mortality was similar to that of the transgenic males. 
Three male transgenic animals from line TG7 were given Captopril in their 
drinking water over the same four week period of blood pressure monitoring. There 
were no initial differences in blood pressure between the transgenic animals treated 
with Captopril and non-treated, non-transgenic animals. There was also very little 
increase in blood pressure and no mortality in the group. This suggests that, as 
expected, the hypertension seen in these animals was mediated through the renin-
angiotensin system. 
5.4 Telemetric Blood Pressure Monitoring 
Direct blood pressure monitoring using the Dataquest telemetric system from 
Data Sciences International, USA, provided continuous blood pressure measurements 
on conscious, unstressed animals (Bidani et al. 1993), see table 5.5 for an example of 
the system output. Due to the sensitivity to anaesthesia and relatively low body weight 
of the transgenic animals, only two male Sprague Dawley line TG2 transgenic and two 
male non-transgenic animals underwent study by this method. 
Both non-transgenic control males demonstrated normal mean blood pressure of 
approximately 100 mmHg and variation in blood pressure of ±10 mmHg over the 
period of study. Using this method both systolic and diastolic blood pressures were 	
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measured directly and output was expressed as mean arterial pressure. Both transgenic 
animals showed severe elevation of blood pressure post-operatively, and in the case of 
transgenic TG2/2532, an inability to reduce blood pressure following the operation. 
Transgenic TG2/2533 did show a steep drop in blood pressure of almost 90 mmHg in 
the 2 hours following the operation. This was followed by a steep increase in blood 
pressure over the subsequent 4-6 hours to return blood pressure to 210 mmHg. Whilst 
TG2/2533s mean blood pressure continued to fluctuate around 190 mmHg TG2/2532 
had a steep rise in mean arterial pressure, peaking at 270 mmHg before going into a 
steady decline. Transgenic TG2/2533 survived 2.5 days after the operation, however, 
TG2/2532 only survived 40 hours post-operatively. Transgenic TG2/2533 also 
showed a steep increase in blood pressure, peaking at 220 mmHg before going into 
steep decline, 60 hours after the operation. 
The telemetric analysis of the TG7 animals took the form of one male transgenic 
and one female transgenic from receiving implants, along with the appropriate non- 
transgenic controls. The transgenic male showed a drop of 50 mn-illg, from 175 
mmHg to 125 mmHg in the 12 hours following the implant operation. The male non-
transgenic animal demonstrated a steady baseline measurement of 115 mmHg with ±10 
mmHg variation throughout the test period. The transgenic male showed some 
periodicity in the measurements taken which becomes more erratic as the trial 
continued. As rats are nocturnal animals, peak activity and blood pressure should 
coincide at approximately Sam. In TGR(mRen-2)27 rats the diurnal rhythm is reversed 
as is often seen in human essential hypertensive patients (Pickering 1990). The results 
obtained from telemetry were not over a sufficient time period for the diurnal rhythm to 
be ascertained. 
The non-transgenic female had a similar baseline measurement to the non-
transgenic male (115 mmHg) with a slightly higher degree of variation (± 15 mmHg). 
The transgenic female had an abnormally low mean blood pressure of 75 mmHg post- 
operatively but over the following 24 hours had an almost exponential rise in blood 
pressure plateauing 36 hours after the operation at 180 mmHg. Any oscillations in the 
blood pressure of the female are difficult to discern. Unlike transgenic animals from 
line TG2 males both transgenics from line TG7 survived for more than five days on 
telemetry. The male transgenic from line TG7 died 3.5 days, and the female transgenic 
also from line TG7 died four days, after the initial readings. Both demonstrated a steep 
rise in blood pressure (10-15 mmHg in 1-2 hours) prior to going into steep decline. 
The different traces produced for TG2 and TG7 were due to the different sampling 
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Figure 5.4 
A: Telemetric data from transgenic and non-transgenic TG2 males (see chapter 2, 
2.5 for methodology) over a three day time period. B: Telemetric data from 
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Figure 5.5 
A: Telemetric data from TG7 transgenic and non-transgenic males (see 
chapter 2, 2.5 for methodology) over a three day time period. B: 
Telemetric data from TG7 transgenic and non-transgenic female over a 
three day time period. 
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The telemetric system allowed continuous blood pressure monitoring on 
conscious, untethered animals. Accurate systolic, diastolic and mean blood pressures 
were obtained using this method. However, due to the comparatively short life span of 
the transgenic animals after the implant operation this procedure did not prove as 
successful as was hoped. If smaller telemetric implants were available it may be 
possible to start the procedure on younger animals that have the potential to survive 
longer. 
CHAPTER 6 
Cardiac and Pathology Data 
6.1 LV:BW Ratios In All Transgenic Lines 
Angiotensin II has been implicated as a growth factor or growth modulator in the 
cardiovascular system and it has been suggested that it plays an important role in 
development and maintenance of cardiovascular hypertrophy (Sadoshima et al. 1993). 
Sadoshima and Izumo found that in culture medium conditioned by stretch cardiac 
myocytes there was at least one factor that caused induction of immediate early genes 
and activation of second messenger systems in non-stretched myocytes. This factor 
was subsequently found to be Ang II and the autocrine secretion was found to play a 
critical role in the stretch-induced hypertrophic response (Sadoshima et al. 1993). 
Animal studies into the role of the RAS hypertrophy have drawn parallels between the 
human condition and heart failure found in the transgenic rat strain TGR(mRen-2)27 
(Paul et al. 1994). 
There are several indications as to the hypertrophic state of cardiac muscle, such 
as interstitial collagen volume fraction, ventricular interstitial fibrosis or perivascular 
collagen area. Such techniques require morphometric analysis, however, heart : body 
weight ratios can be used to give an indication as to the extent of hypertrophic growth. 
As left ventricular hypertrophy (LVH) is the major risk factor associated with 
myocardial failure it is usual to present data in the form of left ventricular weight: body 
weight ratios. 
The animal was sacrificed, weighed, and the heart removed. All blood was taken 
out of the ventricles of the heart and total heart weight taken. The right ventricle was 
then removed from the left ventricle and the left ventricle weighed separately. 
Transgenic males from line TG2 demonstrated an LV:BW ratio of 6.8 ± 0.26: 1 
which was statistically significant when compared to the male non-transgenic ratio of 
4.4 ± 0.21 : 1. Again, the female transgenic animals from line TG2 also had a 
statistically significant ratio of 6.7 ± 0.45 : 1 when compared with the female non-
transgenic ratio of 4.2 ± 0.19 : 1. Sprague Dawley line TG3 transgenic males and 
females demonstrated no statistical significance in the LV:BW ratios when compared 
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Figure 6.1 
Comparison of blood pressure values and HW:BW ratios. The left hand Y 
axis shows systolic blood pressure as measured by tail cuff 
plethysmography. The right hand axis shows heart weight:body weight 
ratios (x10 3). Each time point contained 3 male animals from the groups 
T07, TG12 and negative controls. 
102 
hypertrophy in line TG3 it was not expected that the LV:BW ratio would differ from 
that of the control animals. 
It was suggested by Paul et al (Paul et al. 1994) that the TGR (nRen-2)27 rats 
developed cardiovascular hypertrophy at an age where blood pressure was not 
persistently elevated. In light of this, the transgenic TG7 and TG12 males (n=3) were 
measured for LV:BW ratios and BP at 3 weeks of age (see figure 6.1). Animals from 
both lines TG7 and TG12 demonstrated LV:BW ratios consistent with severe cardiac 
hypertrophy (5.25 ± 0.2 and 5.20 ± 0.48 respectively) when compared with non-
transgenic, age matched, controls (4.15 ± 0.37). When systolic blood pressures were 
measured in all three groups there were no significant differences between TG7, TG12 
or non-transgenic animals (107 ± 5.5, 103 ± 6.45 and 86 ± 2.9 respectively) 
suggesting blood pressure may not have been a determining factor in the onset of 
cardiac hypertrophy. 
Table 6.1 
Weeks TG7 TG7 TG12 I 	TG12 -yes -yes 
of Age HW (g) HW:BW HW (g) HW:BW HW (g) HW:BW 
2 0.32± 5.2±0.26 0.39± 5.0±0.30 0.36± 4.1±0.12 
0.03  0.05  0.07  
3 0.40± 6.5±0.18 0.45± 6.3±0.41 0.44± 4.1±0.15 
0.06  0.09  0.10  
4 0.49± 6.7±0.15 0.56± 6.5±0.46 0.55± 4.3±0.17 
0.07  0.13  0.16  
5 0.61± 6.8±0.11 0.74± 6.6±0.50 0.61± 4.4±0.18 
0.09  0.13  0.18  
6 0.61± 6.8±0.13 0.79± 6.7±0.31 0.61± 4.4±0.21 
0.07  0.16  0.19  
7 0.67± 6.7±.011 0.82± 6.7±0.22 0.65± 4.4±0.25 
0.12  0.20 	1 .23 	1  
Tabulated data of study into the developement of hypertrophy. Data presented as a graph 
with blood pressure analysis in figure 6.1 
6.2 Echocardiology Data From Transgenic Lines TG7 
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and TG12 
The introduction of clinical echocardiology and its broad application in the past 
20 years has greatly changed the ability to detect and quantify hypertensive left 
ventricular hypertrophy in humans. In a study by Gardin et al, echocardiology detected 
left ventricular hypertrophy in nearly 50 per cent of hypertensive patients, whereas no 
more than 5 per cent were identified by electrocardiography and chest radiography 
(Gardin et al. 1979). The routine measurement of left ventricular mass by 
echocardiography is best accomplished using M-mode (one-dimensional) tracings with 
careful placement of the ultrasound beam under two-dimensional (B-mode) guidance. 
With simple measurements of interventricular septal thickness (IVST) and posterior 
wall thickness (PWT) and end diastolic diameter (EDD, the minor axis of the ventricle), 
accurate measurements of the ventricular muscle mass are obtained. This involves the 
use of wall thickness and internal dimensions in an empirically derived regression 
formula developed from echocardiography - autopsy correlations: 
LVmass (LVM) = 1.04[(EDD+PWT+IVS)3 - EDD31/Body Weight 
(Sahn et al. 1978; Devereux et al. 1986) and validated in rats by Jones et al 1992 
(Jones et al. 1992), where 1.04 is the specific gravity of cardiac muscle. 
In humans multivariant analysis revealed that the left ventricular mass 
measurement was a more powerful predictor of prognosis than blood pressure or age 
(Laragh 1992). It should be noted that in patients with hypertension, hypertrophy is 
not an inevitable consequence. Hypertensive left ventricular hypertrophy does not 
appear to be a single morbid process as it is expressed as different geometric patterns in 
different patients. 
In a study by Bruckschlegel et al (1995) (Bruckschlegel et al. 1995), which 
looked at the role of the renin-angiotensin system in chronic pressure-overload 
hypertrophy in rats, it was found that Losartan and Ramipril significantly reduced left 
ventricular mass, twelve weeks after aortic constriction. Hydrazine treated rats, 
however, demonstrated a marked elevation in LVM over the same time period. These 
results were consistent with results found in the renin-dependent model spontaneously 










TG3 Male TG3 Male TG3 Female TG3 Female 









Panel A: Left Ventricular: Body Weight ratios for transgenic line TG2, four 
animals were tested in each group and the error given as one standard deviation 
from the mean. Panel B: Left Ventricular: Body Weight ratios for transgenic line 
TG3, four animals were tested in each group and the error given as one standard 
deviation from the mean. All animals were six weeks of age when tested. 
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Figure 6.3 
Panel A: Left Ventricular : Body Weight ratios for transgenic line TG7, four 
animals were tested in each group and the error given as one standard deviation 
from the mean. Panel B: Left Ventricular : Body Weight ratios for transgenic 
TO 12, four animals were tested in each group and the variance is given as one 
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Figure 6.4 
A: Diagramatic representation of the heart as seen during echocardiographic 
analysis. B: Output from the Toshiba Capasee system, left hand panel M-mode 
(one dimensional), right hand panel B-mode (two dimensional). 
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Figure 6.5 
Left Ventricular Mass Indices for transgenic lines TG7 and TG12 over a period 
of three weeks. Six animals were tested in each group and the error given as 
one standard deviation from the mean. 
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The use of the ultrasound monitor to measure in vivo left ventricular thickness 
was validated in our laboratory by Dr. Whitworth (M.D. thesis) and Dr. Veniant. The 
measurements were taken at various stages of development and compared to the actual 
wet weight of the subjects' left ventricle. There was no statistical difference between 
methods (ANOVA).The study by Jones et al (1992) (Jones et al. 1992) showed the use 
of echocardiography in rats and compared LVM Indices (LVMI) of hypertensive and 
normotensive animals. The LVMI of the spontaneously hypertensive rats (SHR) at 9 
weeks of age was 3.029 and normotensive Donyru rat (DRY) showed an LVMI of 
2.054 at the same age. Between 4 - 7 weeks of age the non-transgenic control animals 
demonstrated LVMIs of 1.5 ± 0.23 - 1.7 ± 0.41. These results were not statistically 
different from the results obtained by Jones et al on the normotensive DRY rats. Both 
Fischer transgenic lines TG7 and TG12 demonstrated LVMIs at 5 weeks of age 
comparable to those seen by Jones et al in the SHR animals at 9 weeks of age. Males 
from line TG7 showed an LVMI of 3.2 ± 0.43 increasing to 3.5 ± 0.47 at six weeks of 
age, with a similar mean value of LVMI at 7 weeks of age. Despite a slightly lower 
LVMI (3.0 ± 0.33), males from line TG12 showed a steep rise in LVMI by week 6 of 
3.6 ± 0.45, reaching a maximum of 3.7 ± 0.41 at 7 weeks of age. It was apparent that 
left ventricular hypertrophy was established by 5 weeks of age in the transgenic 
animals and was maintained throughout the study period. 
Table 6.2 
Weeks of Age TG7 LVMI TG 12 LVMI -ye LVMI 
4 3.2±0.6 3.0±0.4 1.7±0.2 
5 3.5±0.4 3.6±0.5 1.7±0.2 
6 3.5±0.7 3.8±0.3 1.7±0.4 
Tabulated data of study into the developement of hypertrophy by echocardiography. Data 
presented as a graph in figure 6.5 
6.3 Pathological Analysis of All Transgenic Lines 
The first pathological alteration seen in the TGR(ct 1 AT/Ren-2) rats was 
concentric left ventricular cardiac hypertrophy. The extent of the hypertrophy has been 
quantified above. Histological examination of cardiac sections from twenty-five 
transgenic animals revealed that it was indeed hypertrophy, not hyperplasia, as the 
cardiomyocytes had become enlarged. Histology also showed that the hypertrophy 109 
was concentric and restricted to the left ventricle, consistent with involvement with 
hypertension, see figures 6.11. 
During the course of essential hypertension the larger arteries in the kidneys, as 
is the case elsewhere, become rigid and thickened, but their lumina are not seriously 
reduced. These changes also occur in the arcuate arteries but due to their smaller 
calibre, thickening of the wall may result in reduction of the lumen. Ischaemia, lack of 
oxygen due to reduction in circulation, often results from changes in the smaller 
vessels: the interlobular arteries become elongated, with medial fibrosis and fibro-
elastic thickening of the intima resulting in significant narrowing of the lumen. The 
afferent glomerular arteriolar walls become acellular, eosinophilic with varying degrees 
of luminal narrowing. This results in glomerular ischaemia, the glomerular tuft 
becomes shrunken and the capillaries are gradually replaced by pale staining 
homogeneous material, eventually the entire tuft is converted to an acellular sphere (see 
figures 6.6 and 6.7). Despite the loss of individual nephrons renal function is not 
significantly impaired. 
In malignant (accelerated-phase) hypertension the interlobular arteries show 
extensive intimal thickening, due to the formation of fine, concentric layers of 
connective tissue and smooth muscle cells, with severe reduction in the lumen. The 
afferent arterioles show fibrinoid necrosis, the wall being thickened, brightly 
eosinophilic and granular. The necrotic material gives staining reactions of fibrin and 
the lumen is often completely obliterated, or occupied by thrombosis which merges 
with the necrotic wall. The fibrinoid necrosis can extend into the glomerulus, 
involving part or all of the tuft (see figure 6.8). This form of damage was only seen in 
25-30% of the TG7 and TG12 animals. Other glomeruli are less severely damaged and 
show intense capillary dilatation and congestion. The glomerular changes are the direct 
result of acute ischaemia resulting from fibrinoid necrosis of the afferent arterioles. 
These vascular changes of malignant hypertension also occur in other organs although 
the effect is not usually so devastating as in the kidneys. 
The considerable thickening of the intima produces severe narrowing of the 
lumen. The diffuse damage to the vascular tree may be accompanied by intravascular 
coagulation which accentuates the endothelial cell damage. The passage of blood at 
high pressure through a damaged vascular bed with intravascular coagulation causes 
red cell fragmentation - microangiopathic haemolytic anaemia. An example of this 
condition in transgenic rats was shown by Whitworth et al (1995) in a genetic model of 
malignant hypertension. The blood films from malignant phases TGR(mRen-2)27 rats 
all exhibited microangiopathic haemolytic anaemia with red cell fragments, 
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spherocytes, microspherocytes and reticulocytsis. Also in the study by Whitworth et al 
it was reported that in TGR(mRen-2)27 rats microscopic myocardial infarcts were 
found, occasionally related to fibrinoid necrosis of cardiac arterioles. The early lesions 
were cardiomyocytes with focal necrosis, but granulation tissue and focal fibrinotic 
scars suggested a healing response. 
A rise in intraluminal pressure can overcome the normal reflex vasoconstriction 
of an artery. This is more likely to occur when the rate of rise is rapid. The failure to 
resist the pressure causes focal dilatation. There is an increase in permeability and 
plasmatic vasculosis; this is associated with histological evidence of smooth muscle cell 
necrosis resulting in fibrinoid necrosis. The proliferative endarteritis is the healing 
stage of many types of arterial damage, all of which have in common endothelial cell 
injury. The cellular intimal thickening is caused by migration of smooth muscle cells 
through fenestrae in the internal elastic lamina. The cells then orientate themselves 
circumferentially and secrete matrix proteins; the intima is initially oedematous and rich 
in proteoglycans, but later becomes collagenized. 
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Figure 6.6 
Histochemical analysis of renal sections (3im thick) from 6 week old (A) non-
transgenic and (B) transgenic rats. G: Glomerulus, T: Tubule, IA: Interlobular 
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Figure 6.7 
Histochemical analysis of renal sections (3p.m thick) from 6 week old (A) 
Interlobular artery thickening (B) Cresential Damage to the Bowman's Capsule. IA: 
Interlobular Artery, G: Glomerulus. Both panels are stained with eosin and 
haemallum. Panel (A) (xlOO), panel (B) (x400). 
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Histochemical analysis of renal sections (3im thick) from 6 week old (A) non-
transgenic and (B &C) transgenic rats. Both panels are stained with eosin and 
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Figure 6.9 The circle of malignant hypertension. The vascular damage induced by hypertension 
causes renal ischaemia which leads to high plasma levels of vasoconstrictors such as angiotensin H, 
further increasing blood pressure. 
As previously mentioned, there was no abnormal pathology in the transgenic line 
TG3. This was most likely due to the lack of expression of the transgene and as a 
consequence the normal blood pressure demonstrated in these animals. In the 
transgenic transgenic line TG2 there were lesions associated with essential and 
malignant phase hypertension. Despite the variation in severity of the lesions seen, in 
both male and female transgenic animals, all demonstrated pathology consistent with 
high blood pressure. In some cases only interlobular artery thickening or tubule 
dilatation was seen in a few instances, yet in others the renal ischemia was much more 
widespread and pronounced with a few examples of fibrinoid necrosis being recorded. 
The cardiac hypertrophyalready measured by LV:BW ratio was first noted in the 
pathology of transgenic founder TG 1. Target organ damage was also seen in the form 
of liver arteriolar necrosis. 
The renal pathology seen in transgenic lines TG7 and TG 12 was as severe as that 
demonstrated in transgenic line TG2. There was extensive ischemic damage, shrunken 
and damaged glomerular tufts in both male and female samples. The interlobular artery 
thickening and dilated tubules shown in line TG2 were also present in the TG7 and 
TG12 samples. Fibrinoid necrosis was present in a number of samples extending from 
the afferent arterioles into the glomeruli on a number of samples. As seen in samples 
from line TG2, the extent of renal damage varied from very few glomeruli damaged to 
very few glomeruli intact. Other target organ damage included occcassional 
microscopic myocardial infarcts similar to those seen in the sub-population of TGR 
(mRen-2)27. Again, as previously quantitated by echocardiography, one of the most 
prominent pathologies was severe cardiac hypertrophy. All pathology seen in the 
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Figure 6.10 Histochemical analysis of cardiac Sections (3im thick) from 6 week 
old (A) non-transgenic and (B) transgenic rats. MI: Microinfarct. Both panels are 
stained with eosin and haemallum. Panel (A) (xlOO), panel (B) (xlOO). 
CHAPTER 7 
Discussion 
Despite essential hypertension remaining one of the main reasons for initiating 
long-term medical treatment a clear understanding of the causes of high BP in the 
majority of cases has not been reached. Transgenesis has facilitated the study of the 
contribution of individual genes in the models of hypertension, such as the 
TGR(mRen-2)27 rat which resulted in a focus on the extra-renal RAS activity and the 
role of prorenin in hypertension. It is the role prorenin has in hypertension that was the 
focal point for the study undertaken. Refinement of the transgene used in the 
TGR(mRen-2)27 rat meant the role extra-renal prorenin played in the hypertension seen 
in the TGR(mRen-2)27 rat could be addressed directly. 
The expression pattern of the ctlAT/Ren-2 transgene was similar to the 
expression pattern of the a1AT/FIX shown by Jallat et al (Jallat et al. 1990). Despite 
the fact that the a1AT promoter was of human origin, and the experiments performed 
by Jallat et al were in mice, there did not appear to be any species difference when used 
in transgenic rats. In the first series of microinjections three founder rats were 
produced and TG2 was shown to express the transgene, founder TG 1 presumably 
expressed the transgene to caused its premature death and TG3 did not to express the 
transgene as highly as TG2. All the transgenic mice produced by Jallat et al contained 
an endogenous intron from the human FIX gene, with the exception of pTG49 15 and 
the minigene constructs. The transgenes under the control of the c1AT promoter but 
lacking any intronic sequence did not produce expressing transgenic mice. 
The progeny from the founder mice containing the a1AT-genomic FIX construct 
produced low litter numbers. This may have been a problem unique to the C57 BL6 x 
SJ2 hybrid female mice used. The litter numbers in the a1AT/Ren-2 transgenic rat 
lines appeared normal. Despite low expression levels of the human FIX protein Jallat 
et al reported a personal communication from W. Dalemans which stated high level 
expression of a heterologous protein using the same x1 AT regulatory sequence. 
Expression in the transgenic lines presented here appeared low, only detectable 
by poly A+ Northern blot hybridisation and RNase protection, yet the protein levels of 
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plasma prorenin were similar, or greater, than that seen in the TGR(mRen-2)27 rats. 	
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The genomic Ren-2 transgene expression, however, in the TGR(mRen-2)27 rats was 
detected by total RNA Northern blot hybridisation. 
Measurement of renin is performed with a kinetic assay where it cleaves Ang I 
from angiotensinogen. Angiotensin I is subsequently measured by direct RIA. The 
concentration of renin is expressed as the hourly rate of Al generation. In this 
quantitation one molecule of renin can generate many molecules of Al. However, the 
lysosomal enzyme cathepsin D is capable of cleaving Al and All in vitro (Hackenthal et 
al. 1978), and is released by cell death. Cathepsin D has a lower activity at the pH 
used for the renin assay (pH 6.0-7.4) but it is not completely inactive (Dorer et al. 
1978). 
The measurement of plasma renin activity is a convenient method for estimating 
the action of the renin system, however, its interlaboratory reproducibility is poor. 
Alternative methods exist such as direct immunoradiometry (Morganti et al. 1995) and 
HPLC of Al and All. The methodology used in this thesis is prone to variation when 
measuring small changes in plasma RAS but if comparing large differences is valid. 
As mentioned the plasma RAS parameters of the alATIRen-2 rats were similar 
to that reported in the TGR(mRen-2)27 rats, with the notable exception of the plasma 
prorenin levels in the transgenic line TG2. This Sprague-Dawley line showed plasma 
prorenin levels 4-5 times greater than those measured in the Fischer lines TG7 and 
TG12. As expression of the transgene at the RNA level appears to be relatively 
equivalent on the lines TG2, TG7 and TG12 the reason for the higher protein level in 
line TG2 is unclear. Despite the high plasma prorenin in all the a1AT/Ren-2 lines, 
plasma renin was not significantly elevated. The percentage of transgene derived renin 
was 70->80% in all o1AT/Ren-2 lines, however, transgene derived prorenin was in 
excess of 95%. These data suggest that there may be a form of feedback mechanism to 
explain the differences in the transgene derived pro and active renin. It also shows that 
the prorenin to renin 'tconvertase" in rat can activate mouse Ren-2 prorenin. It would 
be very informative to determine whether blood pressure in transgenic rats correlated 
with transgene expression levels. Taking blood pressure measurements and RNA 
samples on a weekly basis, from a number of transgenic lines it would be possible, by 
RNase protection, to show any relationship between transgene expression and blood 
pressure. 
As all rats in this study were anaesthetized before tail cuff plethysmography it has 
been suggested that the halothane may have affected the blood pressure readings. The 
anaesthetic was the minimum required to keep the animal still during the procedure (1-
2% halothane in 02).  If it had been feasible, however, to train every rat to remain still, 
in a Perspex cylinder the results would have been more physiologically relevant and 118 
possibly lowered the variation within groups. 
The blood pressure increase seen in the a 1 AT/Ren-2 rats was markedly different 
to the TGR(mRen-2)27 rat. The TGR(mRen-2)27 rat reached a plateau of systolic 
blood pressure of 210mmHg at ten weeks of age before entering an accelerated phase 
hypertension, whereas the alATIRen-2 rats reached a maximum blood pressure of 
200mmHg by seven weeks of age. The plasma prorenin levels on the lines TG7 and 
TG 12 were significantly elevated at four weeks of age and continued elevation to five 
weeks of age, whereas blood pressure continued to rise to seven weeks of age. This 
suggests there is no direct correlation between plasma prorenin and blood pressure. It 
was suggested by Lemmer et al (Lemmer et al. 1993) that there was an alteration to the 
circadian rhythm of blood pressure in the TGR(mRen-2)27 rat. In secondary forms of 
hypertension the normal pattern of circadian variation is frequently disturbed with 
nocturnal decrease in blood pressure failing to occur (Pickering 1990). Despite the 
short period of telemetric monitoring of the TGR((x 1 AT/Ren-2) rats the periodicity in 
the blood pressures that is present does not appear to be disturbed. The telemetric 
analysis does reveal to what extent the blood pressure increase in the transgenic lines 
TG2 and TG7. 
It has been suggested that as all transgenic founders were maintained on 
Captopril, female founders may have passed on a protective effect, caused by the ACE 
inhibitor. To answer this males from lines TG13 and TG14 could be bred with non 
transgenic females and a comparison made between blood pressure measurements 
taken from offspring derived from transgenic and non-transgenic mothers. 
In humans obesity is possibly one of the best predictors for risk of development 
of hypertension. The Framingham Study showed data on the tracking of body weight 
and blood pressure (Gordon et al. 1976). It demonstrated the relationship between 
degree overweight and risk of hypertension also that an individual who was initially 
hypertensive had a greater chance of gaining weight over time than in normotensives. 
Rats fed a high fat diet, and allowed to overeat and become obese, also developed 
hyperinsulinaemia, elevated sympathetic activity and hypertension (Hwang et al. 
1987). 
This does not address the strong genetic disposition in human obesity. The 
Zucker strain represents an animal model that combines heredity with obesity, insulin 
resistance and hyperinsulinaemia (Kasiske et al. 1992). Kurtz et al, however, 
suggested only 50% of studies showed development of hypertension in Zucker obese 
rats (Kurtz et al. 1989). Despite elevated blood pressure at three weeks of age in lines 
TG2, TG7 and TG12 they showed no increase in body weight when compared to 
normotensive controls. In fact all three transgenic lines demonstrated a significantly 
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lower weight gain (TG2 p< 0.05, TG7 p< 0.01 and TG12 p< 0.01) than normotensive 
controls. There was no significant difference in food intake by the transgenic and non-
transgenic animals. There may have been a difference in metabolic rate and certainly 
the transgenic animals displayed some polyuria in the late stages of the hypertensive 
phenotype, possibly contributing to the apparent difference in weights. 
The immunohistochemical data presented showed DAB/1-1202 staining in only a 
few JG cells in non-transgenic and transgenic animals as is consistent with low 
endogenous renin production in the normotensive situation. If hypertension occurs 
gradually endogenous renin production decreases. If, in the case of malignant 
hypertension, severe occlusion of the interlobular arteries occurs in can produce local 
areas of hypotension in the kidney and endogenous renin production increases as a 
result of the baroreflex response. 
Despite pathological evidence that some transgenic samples demonstrated 
malignant hypertension (fibrinoid necrosis in the afferent arteriole) this was not shown 
immunohistochemically. This could be due to the extent of renal damage already 
present with upwards of 75% of glomeruli damaged in some cases, obscuring any 
response. It could be that serial sections through a kidney with pathological evidence 
of malignant hypertension would be necessary to be certain of observing this 
phenomena. The immunohistochemical staining seen in the small arteries of the heart 
in transgenic samples from the line TG7 may provide a link between the hypertrophy 
and hypertension seen. If, as suggested by von Lutterori, renin is the only constituent 
of the RAS not synthesised in cardiac tissue this may be evidence of uptake of 
pro/active renin from the circulation. Without in situ data it is impossible to know 
whether this is uptake or de novo synthesis of prorenin. If either case is true All could 
be formed locally in the heart and could therefore lead to hypertrophy before 
hypertension. 
Certainly the hypertrophy, as measured by echocardiography, seems to be 
present in both TG7 and TG12 transgenic lines before the hypertension is fully 
established. The heart:body weight data from, two and three week old TG7 and TG12 
transgenic males also supports the finding that hypertrophy may be established before 
the onset of elevated blood pressure. Although hypertrophy is often thought of as an 
adaptive process in response to high blood pressure it may be in this case that the 
abnormal levels of prorenin in the plasma can lead to locally generated cardiac All. 
This All could then cause a hypertrophic response that consequently would have an 
effect on blood pressure. It would be possible with the use of AT1 receptor 
antagonists, eg. Mibefridil to determine whether or not the hypertrophic response in 
this case was mediated through All. By administering enalapril at doses that lower 120 
blood pressure it would be possible to ascertain if the hypertrophy was purely a result 
of high blood pressure. 
The renal lesions seen in all transgenic lines are consistent with high blood 
pressure effects either chronic or acute. There is a hypertrophic thickening of the 
interlobular arteries, damage to glomerular tufts and cresential thickening seen in some 
Bowman's capsules. As with the transgenic line TGR(mRen-2)27, in certain cases 
fibrinoid necrosis was seen in the afferent arterioles as an indication of malignant 
hypertension in the ctlAT/Ren-2 lines. However, despite malignant phase 
hypertension having been demonstrated with a specific genetic cross of Sprague 
Dawley, TGR(mRen-2)27 rats, fibrinoid necrosis was seen in both Sprague Dawley 
and Fischer backgrounds for the ctlAT/Ren-2 lines. This suggests that the malignant 
phase hypertension seen in the a1AT/Ren-2 lines is independent of genetic 
background. 
The genetic background of individual xl AT/Ren-2 transgenic lines does not 
appear to have any effect on the phenotype seen. The TGR(mRen-2)27 rats were 
generated on an outbred Sprague-Dawley background as were TG1, TG2 and TG3 
presented here. As the Sprague-Dawley strain was outbred there were some genetic 
differences between individual animals. The TG4-TG 16 animals were generated on an 
inbred FischerI17344 background making it possible to perform organ transplants and 
more classical genetic experiments on these lines. 
The hypertension seen in the alATfRen-2 transgenic animals was most likely a 
result of activation of the high plasma prorenin. The evidence for this is the fact that 
the majority of plasma active renin in the transgenic animals was derived from 
transgene expression. As the transgene expressed prorenin in the liver, any transgene-
derived plasma renin must be the result of activation of this prorenin in organ or organs 
unknown. 
Investigation of the specific role elevated plasma prorenin has in these transgenic 
animals could employ site directed mutagenesis to look at uncleavable prorenin. 
Alteration of the cleavage site of prorenin may determine the physiological role of 
prorenin. Similarly alteration of the glycosylation sites in the Ren-2d molecule may 
produce evidence as to the role of glycosylation in renin proteins. 
Vertebrate aspartyl proteases, such as chymosin, pepsin and renin are 
synthesised as inactive zymogens and are then converted to active enzymes by limited 
proteolysis. This enzymatic activity is expressed by the exposure of the zymogen to 
acidic conditions. This activation is a reversible, unimolecular reaction (Leckie et al. 
1980), suggesting a conformational change leading to an opening of the substrate 121 
binding cleft as a result of acidification. 
Site-directed mutagenesis (SDM) has been used to investigate the role positively 
charged residues (Arg 10, Arg 15, Arg 20) in the prosegment play in acid activation 
[Yamauchi, J Biochem 1990]. When these residues were changed to noncharged 
residues the prorenin mutants were active without acid treatment. The hypothesis that 
was proposed was that the positively charged residues stabilise the inactive prorenin 
structure through electrostatic interaction between the prosegment and the active 
enzyme. 
In order to determine the physiological role uncleaved prorenin has, if any, in the 
a 1 anti-trypsinlRen-2 transgenic animals it seems reasonable to alter the amino acid 
sequence at the pro/renin cleavage site in such a way that it would no longer be 
activatable to renin by any endogenous enzyme (see figure 7.1 for possible strategies). 
Possible strategies to mutate the pro/renin cleavage site may include substitution of the 
Lys-61, Arg-62 recognition site with Ala-Ala which would probably provide little 
chance of cleavage. However, there would be an alteration to the local charge ratio 
around these residues which could alter the structure of the cleavage site. Another 
possibility if the local charge difference caused by the Ala-Ala mutation proved to alter 
the structure of the protein is to produce a more conservative mutation such as the Lys 
Arg site mutated to Lys Ser. 
Other possibilities for extending the transgenic project could include a chimeric 
gene using segments from the mouse Ren-2d cDNA fused with sequence from rat renin 
cDNA, making a complete renin cDNA. It may then be possible to identify the 
functional unit(s) of the mouse Ren-2d cDNA that cause a rise in blood pressure, when 
rat renin cDNA in transgenic rats does not. Also useful would be a tissue specific, 
inducible promoter. This would allow an increase in plasma prorenin at any given time 
by the addition of an inducing agent. It may also allow study of the effects prorenin 
has on individual organs as in the case of cardiac hypertrophy. It may also be possible 
to titrate the level of plasma prorenin required for a given rise in blood pressure, if the 
link between prorenin and blood pressure in these animals is a direct one. 
The aim of the project was to elucidate the role that circulating prorenin has in the 
TGR(mRen-2)27 rat. To that end these transgenic lines show that prorenin, 
irrespective of the site of origin, can produce a hypertensive phenotype. They also 
raise a number of important questions as to the role prorenin, and tissue RASs play in 
the phenotype. If the immunohistochemical staining has a relevance then there may be 
transport mechanisms seen in the renal tubules and small cardiac arteries. Prorenin as a 
physiological significant molecule is a contentious subject yet there is no evidence here 
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that any other constituent of the RAS is significantly altered. The results demonstrate 
that in the a1AT/Ren-2 rat extra-renal expression of Ren-2 prorenin, directly or 
indirectly, results in hypertension with extreme cardiac hypertrophy. This model also 




Media used in transgenic generation 
Table 2.2 Components of M2 and M16 Media 
Compound M2 M16 
MM 	/ mm 	/ gl 1  
NaCI 94.66 94.66 
KCI 4.78 4.78 
CaCl2.2H20 1.71 1.71 
KH2PO4 1.19 1.19 
MgSO4.7H0 1.19 1.19 
NaHCO3 4.15 25.00 
HEPES 20.85 - 
Sodium Lactate 23.28 23.28 
Sodium Pyruvate 0.33 0.33 
Glucose 5.56 5.56 
BSA 4.0 4.0 
Penicillin G, K Salt 
(Final Conc., 100U/ml  
0.06 0.06 
Streptomycin sulphate 
(final cone., 50 mg/ml)  
0.05 0.05 
Phenol Red 0.01 0.01 
ddH20 to 11 to 11 
Adapted from (Hogan et al. 1986). 






Week TG2 TG3 Control TG7 TG12 Control 
4 71.2 82.0 85.4 73.5 84.7 85.6 
± 7.8 ± 4.1 ± 4.6 ± 5.7 ± 4.9 ±6.3 
5 103.7 123.9 132.7 86.9 111.8 128.3 
± 8.6 ± 13.6 ± 9.3 ± 9.6 ± 3.3 ±9.0 
6 118.3 131.7 137.1 89.8 117.4 138.5 
± 14.4 ± 15.6 ± 11.1 ± 4.1 ± 8.4 ± 9.2 
7 120.1 138.9 143.0 100.3 122.1 148.2 
± 11.5 ± 12.4 ± 13.5 ±10.5 ± 9.2 ±10.6 
Tabulated results of weight gain (in grammes) in TGR(alATfRen-2) rats. See figures 5.113 and 
5.2B for graphs. 
Table 5.3 









4 90 100 100 100 90 100 100 
5 80 100 100 100 80 90 100 
6 40 100 100 100 40 50 100 
7 10 90 100 100 20 10 100 
Survival rates of TGR(alATIRen2) rats given as a percentage, see figures 5.1A and 5.2A for 




Week TG2 TG7 TGI2 Non-transgenic 
Controls 
4 122 137  128 134  134 121  88 91  
129 124  124 129  116 130  90 85  
127 121  127 133  119 125  86 86 
135 127 x= 
128.3 
131 125 x= 
 129.0 
128 129 x= 
125.9 
87 88 x= 
 87.5 
131 130 SD= 
5.2 
130 129 SD= 
 3.2 
126 131 SD= 
5.7 
87 87 SD= 
 1.8 
5 148 149  141 151  195 165 90 96  
140 136  158 149  168 176 92 94  
137 143  162 147  159 192 95 94  
145 140 x= 
43.1 
153 150 x= 
152.1 
167 171 =x= 
174.8 
91 93 X-- 
 93.3 
149 146 SD= 
4.7 
155 156 SD= 
5.9 
180 175 SD= 
11.5 
95 93 SD= 
 1.9 
6 168 171  166 168  185 180 98 106  
166 171  162 164  172 176 - 102 105  
177 170  172 169  173 179 - 101 99  
179 167 x= 
171.6 
175 165 - x= 167.6 172 =182 x= 178.2 104 102 ____ X-- 101.9 
181 166 SD= 
5.5 
168 167 SD= 
 3.8 
184 179 SD= 
 4.5 
100 102 SD= 
 2.6 
7 177 202  168 184  166 165  107 100  
189 181  192 172  169 165  108 102  
194 176  185 177  172 173  108 104 








169 176 x= 
 170.4 
110 105 x= 
 105.1 L1 73 187 SD= 
8.9 
176 172 SD= 
 8.1 
177 173 SD= 
 4.5 
104 103 SD= 
 3.1 
Tabulated results (in mmHg) from four week tail cuff plethysmography studies. Each individual value 
is the result of five systolic blood pressure measurements. See figure 5.3 for graphical representation 
of these results. 
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